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PREFACE 
 
“But we have this treasure in earthen vessels, that the excellence of the power may be of God and not 
of us. We are hard-pressed on every side, yet not crushed; we are perplexed, but not in despair; 
persecuted, but not forsaken; struck down, but not destroyed—” 
9-4:7 iansII Corinth  
 
It has been a long adventurous journey since 2011 when the idea of this project was first 
conceptualized. Like any worthwhile expedition, it has been paved with patches of good road 
interspersed with many instances of rocky and bumpy surface. However, I thank God for carrying me 
thus far. I believe that without Him none of this would have been possible. For “who shall separate us 
from the love of Christ? Shall tribulation, or distress, or persecution, or famine, or nakedness, or peril, 
or sword?” (Romans 8:35). I believe that this project was a call from God to do something of potential 
benefit to a group of vulnerable patients that are often discriminated against because they are too poor 
or too sick for anyone to try and offer them anything. Because of limited resources, HIV-positive 
renal failure patients with uncontrolled HIV infection are excluded from state-sponsored dialysis 
programme and told to fend for themselves and pay for private dialysis or go home and die. They are 
excluded from even peritoneal dialysis even though it is not limited by the number of available 
haemodialysis machines. This project was aimed at exploring the use of peritoneal dialysis 
particularly for indigent patients who would have otherwise not been offered anything due to their 
HIV infection control. Even prolonging one life for a month, a year or two would have been mission 
accomplished. 
 
  
ii 
 
DECLARATION 
 
I   Kwazi Celani Zwakele Ndlovu   declare that  
(i) The research reported in this dissertation, except where otherwise indicated, is my original 
work.  
 
(ii) This dissertation has not been submitted for any degree or examination at any other 
university.  
 
(iii) This dissertation does not contain other persons’ data, pictures, graphs or other information, 
unless specifically acknowledged as being sourced from other persons.  
 
(iv) This dissertation does not contain other persons’ writing, unless specifically acknowledged as 
being sourced from other researchers. Where other written sources have been quoted, then:  
(a) their words have been re-written but the general information attributed to them has been 
referenced;  
(b) where their exact words have been used, their writing has been placed inside quotation 
marks, and referenced.  
(v) Where I have reproduced a publication of which I am an author, co-author or editor, I have 
indicated in detail which part of the publication was actually written by myself alone and 
have fully referenced such publications.  
 
(vi) This dissertation does not contain text, graphics or tables copied and pasted from the Internet, 
unless specifically acknowledged, and the source being detailed in the dissertation and in the 
References sections.  
 
 
 
Student signature:______________________________  Date:__18 January 2017_______ 
 
 
 
Supervisor signature: ______________________________  Date: ______________________ 
  
iii 
 
DEDICATION 
 
“The ideal man bears the accidents of life with dignity and grace, making the best of circumstances.” 
- Aristotle 
 
I dedicate this thesis to the loving memory of my late father Mlamuli Mathews Ndlovu and my late 
grandmother Gladys Msomi, whose mental resilience and ability to rise above it all, continues to serve 
as a great source of motivation and inspiration. Although never having achieved great academic 
qualifications living in apartheid suppressive times, they made the best of what they had and had a 
die-hard attitude which continues to live in us today.  
  
iv 
 
ACKNOWLEDGEMENTS 
There are many people without whom this project might not have been completed, and to whom I am 
greatly indebted. 
 
To my family, who stood by me when the road was tough, and I was scarcely available throughout the 
four-year journey, I am forever grateful. 
 
To my supervisor, Prof Assounga who has been a pillar of support, guidance, and encouragement, I 
am continually thankful particularly of your patience and kindness. May God richly bless you. 
 
To our research administrator, Mr. James Bukenge Lukobeka who was the steady hand that supported 
this project to its completion. I am grateful for all your work which at times was beyond your scope of 
practice. You were a valuable asset that allowed this ship to reach its destination. 
 
To our research nurse, Sr. Lindiwe Beryl Mtambo who came at the right time and assisted to the best 
of her ability without fail, I am forever in your debt. 
 
To the staff of Inkosi Albert Luthuli Central Hospital Renal Unit, particularly Sr. Busisiwe Msomi, Sr. 
Nontokozo Buthelezi and Sr. Elizabeth Margaret Van Rooyen who came to my rescue numerous 
times, there are no words to express the appreciation and gratitude I feel. 
 
To Lancet Laboratories, particularly Dr. AK Peer, I am endlessly appreciative for laboratory 
assistance you provided when we needed it most. 
 
To the funders who took a chance on me and my project, and gave us resources without which this 
project would never have succeeded, I am eternally thankful 
1. International Society of Nephrology Clinical Research Program 
2. Discovery Foundation Academic Fellowship Award 
3. South African Medical Research Council Clinician Researcher Programme 
4. South African National Research Foundation Thuthuka Funding Instrument 
5. University of Kwazulu-Natal College of Health Sciences Seed Funding  
6. Grant number: R24TW008863 from the Office of the U.S. Global AIDS Coordinator and the U. 
S. Department of Health and Human Services, National Institutes of Health (NIH OAR and NIH 
ORWH). 
 
 
v 
 
TABLE OF CONTENTS 
Preface ..................................................................................................................................................... i 
Declaration .............................................................................................................................................. ii 
Dedication .............................................................................................................................................. iii 
Acknowledgements ................................................................................................................................ iv 
Table of contents ..................................................................................................................................... v 
Lists of figures, tables and acronyms ................................................................................................... viii 
List of Figures .................................................................................................................................. viii 
List of Tables ..................................................................................................................................... ix 
List of Acronyms ................................................................................................................................ x 
ABSTRACT .......................................................................................................................................... xii 
CHAPTER 1: INTRODUCTION ........................................................................................................... 1 
1.1 HIV and renal disease .............................................................................................................. 1 
1.1.1 HIV-associated nephropathy ............................................................................................ 2 
1.2 Treatment options .................................................................................................................... 2 
1.3 Peritoneal dialysis .................................................................................................................... 3 
1.3.1 Health economics of Peritoneal Dialysis ......................................................................... 4 
1.3.2 Complications of Peritoneal Dialysis ............................................................................... 5 
1.3.3 CAPD associated peritonitis ............................................................................................ 6 
1.3.4 Risk factor for CAPD associated peritonitis .................................................................... 6 
1.4 CAPD and HIV infection ........................................................................................................ 8 
1.4.1 Outcomes of CAPD in HIV infection .............................................................................. 8 
1.5 HIV shedding in PD fluid ........................................................................................................ 9 
1.6 The South African HIV epidemic .......................................................................................... 10 
1.7 Renal replacement options in South African ......................................................................... 11 
1.8 Rationale ................................................................................................................................ 12 
1.9 Objectives .............................................................................................................................. 12 
1.10 Overview of Methodology..................................................................................................... 13 
1.10.1 Study design and sample population ......................................................................... 13 
1.10.2 Inclusion Criteria ....................................................................................................... 14 
1.10.3 Group stratification: .................................................................................................. 14 
1.11 Overview of the Thesis .......................................................................................................... 14 
CHAPTER 2: CONTINUOUS AMBULATORY PERITONEAL DIALYSIS IN PATIENTS WITH 
HIV AND END-STAGE RENAL FAILURE ............................................................................ 16 
CHAPTER 3: PERITONEAL DIALYSIS PERITONITIS OUTCOMES IN PATIENTS WITH HIV 
AND END-STAGE RENAL FAILURE: A PROSPECTIVE COHORT STUDY .................... 31 
vi 
 
CHAPTER 4: STAPHYLOCOCCAL NASAL COLONISATION AND PERITONEAL DIALYSIS 
INFECTIVE OUTCOMES IN PATIENTS WITH HIV AND END-STAGE RENAL 
FAILURE: A PROSPECTIVE COHORT STUDY ................................................................... 43 
Abstract ............................................................................................................................................. 45 
Introduction ...................................................................................................................................... 47 
Methods ............................................................................................................................................ 48 
Study population .......................................................................................................................... 48 
Enrolment and follow-up ............................................................................................................. 49 
Microbiology ................................................................................................................................ 49 
Definitions .................................................................................................................................... 50 
Mupirocin exposure...................................................................................................................... 51 
Statistical analysis ........................................................................................................................ 51 
Results .............................................................................................................................................. 52 
Patients’ characteristics ................................................................................................................ 52 
Study end points ........................................................................................................................... 52 
Staphylococcal nasal carriage ...................................................................................................... 53 
Staphylococcal peritonitis ............................................................................................................ 53 
Exit site and tunnel infections ...................................................................................................... 55 
Mupirocin exposure...................................................................................................................... 56 
Discussion ......................................................................................................................................... 57 
Conclusions ...................................................................................................................................... 61 
List of abbreviations ......................................................................................................................... 62 
Declarations ...................................................................................................................................... 62 
References ........................................................................................................................................ 64 
Figure legends................................................................................................................................... 71 
Tables  ............................................................................................................................................... 74 
CHAPTER 5: DETECTION OF HUMAN IMMUNODEFICIENCY VIRUS-1 RIBONUCLEIC 
ACID IN THE PERITONEAL EFFLUENT OF RENAL FAILURE PATIENTS ON HIGHLY 
ACTIVE ANTI-RETROVIRAL THERAPY ............................................................................. 86 
CHAPTER 6: SYNTHESIS .................................................................................................................. 97 
Conclusion ...................................................................................................................................... 102 
Recommendations and future work ................................................................................................ 102 
REFERENCES ................................................................................................................................... 104 
APPENDIX 1: ETHICS APPROVAL ................................................................................................ 109 
APPENDIX 2: INFORMATION DOCUMENT ................................................................................ 111 
APPENDIX 3: CONSENT DOCUMENT .......................................................................................... 113 
vii 
 
APPENDIX 4: DATA CAPTURE SHEETS ...................................................................................... 115 
  
viii 
 
LISTS OF FIGURES, TABLES AND ACRONYMS 
List of Figures 
Chapter 2 
Fig. 1: Kaplan-Meier estimates for catheter patency censored for mortality, catheter loss not related to 
technique failure and loss to follow-up ................................................................................................. 20 
Fig. 2A: Kaplan-Meier estimates for mortality outcome censored for catheter loss and loss to follow-
up for all-cause mortality ...................................................................................................................... 23 
Fig. 2B: Kaplan-Meier estimates for mortality outcome censored for catheter loss and loss to follow-
up for all-cause mortality according to baseline CD4 count ................................................................. 23 
Fig. 3: Kaplan-Meier estimates for first peritonitis event censored for mortality, catheter loss and loss 
to follow-up ........................................................................................................................................... 24 
 
Supplementary Fig. 1: Kaplan-Meier estimates for all-cause hospital admissions censored for 
mortality, catheter loss and loss to follow-up ....................................................................................... 27 
 
Chapter 3 
Fig. 1. Kaplan-Meier survival estimates for peritonitis episodes excluding relapses censored for 
mortality, catheter loss, and loss to follow-up ...................................................................................... 38 
Fig. 2. Kaplan-Meier estimates for catheter patency according to HIV status censored for mortality, 
loss to follow-up, and catheter removal unrelated to technique failure ................................................ 41 
Fig. 3. Kaplan-Meier estimates for catheter patency according to peritonitis experience (1 or more 
peritonitis episodes during follow-up) censored for mortality, loss to follow-up, and catheter removal 
unrelated to catheter failure .................................................................................................................. 41 
 
Chapter 4 
Figure 1— Staphylococcal peritonitis according to human immunodeficiency virus infection status. 71 
Figure 2— S. aureus peritonitis according to human immunodeficiency virus infection status. .......... 72 
Figure 3— S. aureus peritonitis in relation to S. aureus nasal carriage. ............................................... 73 
 
Chapter 5 
Fig. 1: Scatter plot of viral load logs in PD fluid and plasma according to specimen batches ............. 91 
 
  
ix 
 
List of Tables 
Introduction 
Table 1: Survival and complication rates in different studies  ................................................................ 9 
Table 2: Study design summary ............................................................................................................ 13 
Chapter 2 
Table 1: Baseline Characteristics  ......................................................................................................... 19 
Table 2: Crude Outcomes ..................................................................................................................... 21 
Table 3: Multivariable Analysis ............................................................................................................ 25 
 
Supplementary Table 1: Patient outcomes at one year ......................................................................... 28 
Supplementary Table 2: First peritonitis events.................................................................................... 29 
Supplementary Table 3: Indications for first hospital admission .......................................................... 30 
 
Chapter 3 
Table 1: Baseline characteristics ........................................................................................................... 35 
Table 2: Peritonitis outcomes at 18 months .......................................................................................... 36 
Table 3: Peritonitis episode culture results ........................................................................................... 37 
Table 4: Incidence rates and Cox proportional hazard univariate analysis ........................................... 39 
Table 5: Cox proportional hazard univariate and multivariate analyses: risk factors vs. peritonitis and 
technique failure .................................................................................................................................... 40 
 
Chapter 4 
TABLE 1: Baseline Characteristics of the Patients .............................................................................. 74 
TABLE 2: Patient Outcomes at 18 Months .......................................................................................... 78 
TABLE 3: Incidence Rates and Cox Proportional Hazard Univariate Analysis ................................... 82 
TABLE 4: Cox Proportional Hazard Univariate and Multivariate Analyses: Risk Factors vs. 
Staphylococcal Peritonitis ..................................................................................................................... 84 
 
Chapter 5 
Table 1: Baseline characteristics of study participants ......................................................................... 90 
Table 2: HIV-1 RNA in Plasma and CAPD effluents........................................................................... 91 
Table 3: Clustered univariate and multivariable logistics regression analysis for the detectability of 
HIV-1 viral particles in CAPD effluents and Plasma ........................................................................... 92 
 
Supplementary Table 1: Detection of HIV-1 RNA in Plasma and CAPD effluents ............................. 95 
  
x 
 
List of Acronyms 
AIDS  Acquired Immune Deficiency Syndrome 
AIN Acute interstitial nephritis 
ATN Acute tubular necrosis 
Alb Albumin 
ART Anti-retroviral therapy 
ARV Anti-retroviral 
APOL1 Apolipoprotein L1 
AC arm circumference 
BMI Body mass index 
CI  95% Confidence Interval 
CPM Calcium, Phosphate and Magnesium 
CKD Chronic kidney disease 
CD4 Cluster of Differentiation 4 cell or T4 ‘helper’ lymphocyte  
CAPD  Continuous Ambulatory Peritoneal Dialysis 
CNS  Coagulase-negative staphylococci 
CRP C-reactive protein 
ELISA  Enzyme Linked Immuno Sorbent Assay 
ESRD  End-stage renal disease 
ESRF  End-stage renal failure 
ESR Erythrocyte sedimentation rate 
eGFR Estimated glomerular filtration rate  
ESI exit-site infection 
FGF Fibroblast growth factor  
FSGS  Focal Segmental Glomerulosclerosis 
GFR Glomerular Filtration Rate 
HR Hazard ratio 
HAART Highly active antiretroviral treatment 
HD Haemodialysis 
HIV Human immunodeficiency virus 
HIVAN  HIV nephropathy 
HIVIC HIV associated immune complex disease 
IRR Incident rate ratio 
IALCH Inkosi Albert Luthuli Central Hospital 
IL-1 Interleukin-1beta 
IL-6 Interleukin-6 
ISPD International Society of Peritoneal Dialysis 
xi 
 
IP Intraperitoneal 
INH Isoniazid 
KEH King Edward Hospital 
MAMC Mid-arm muscle circumference 
MRSA Methicillin-resistant Staphylococcus aureus 
MYH9 Myosin, heavy chain 9 
NHLS  National Health Laboratory Service 
NGAL Neutrophil gelatinase-associated lipocalin 
NSAIDS Non Steroidal anti-inflammatory drugs 
OR Odds Ratio 
pmp Per million people 
PD  Peritoneal dialysis 
PDE Peritoneal dialysis effluent 
PDET Peritoneal Dialysis Exchange Tubing 
PEW  Protein Energy Wasting 
RCT Randomized Control Trial 
RPR Rapid Plasma Reagin (screening test for syphilis) 
RRT  Renal Replacement Therapy 
SES Socio-economic status 
SGA Subjective global assessment 
SSA  sub-Saharan Africa 
TGF Transforming growth factor 
TB  Tuberculosis 
TFT Thyroid function test 
FT3 Free Triiodothyronine 
UF Ultrafiltration 
USA United states of America 
WC Waist circumference 
WHO World Health Organisation 
WBC White Blood Cells 
 
  
xii 
 
ABSTRACT  
Continuous ambulatory peritoneal dialysis (CAPD) is cost effective, easy to learn, and requires no 
complex equipment, thus, is well-suited as a home dialysis modality in areas with distant or limited 
dialysis facilities. We aimed to evaluate the effects of HIV infection on CAPD outcomes in dialysis-
requiring end-stage renal disease (ESRD) patients. 
 
The first report (Chapter 2) evaluated the effects of HIV-infection on primary end points of mortality 
and catheter failure, and primary morbidity outcomes of first peritonitis and hospital admissions at one 
year. HIV infection was not shown to adversely influence catheter failure rates or patency; however, 
uncontrolled HIV infection was associated with increased relative risk of mortality, first peritonitis, and 
hospital admissions.  
 
The second report (Chapter 3) evaluated the effects of HIV infection on all peritonitis episodes, 
including relapses and subsequent episodes at 18 months. HIV infection was associated with increased 
risk for overall peritonitis and peritonitis relapse. Although peritonitis was also associated with adverse 
catheter failure outcomes, HIV infection was not shown to result in significantly increased catheter 
failure rates at 18 months. 
 
The third report (Chapter 4) evaluated the effects of HIV infection on nasal carriage of Staphylococcus 
aureus, staphylococcal peritonitis, and catheter infection rates. HIV infection was shown to be a risk 
factor for methicillin-resistant S. aureus nasal colonisation, and that it can increase the risks of 
coagulase-negative staphylococcal peritonitis and S. aureus catheter infections in association with S. 
aureus nasal carriage. 
 
The fourth report (Chapter 5) evaluated shedding of HIV-1 particles into CAPD effluents. HIV particles 
were shown to be shed in detectable amounts into CAPD effluents even in patients with suppressed 
plasma viral load, raising concerns of a localised sanctuary site and potential infectivity of HIV-positive 
CAPD patients on a full complement of antiretroviral therapy. 
 
The thesis contributes to our understanding of the morbidity and mortality associated with 
uncontrolled HIV infection in ESRD patients on CAPD, the shedding of HIV-1 particles into CAPD 
effluents, and the resistance profiles of S. aureus colonisers and the organism patterns that are likely 
to cause infection, which may assist in guiding appropriate antibiotic therapy and prophylaxis. 
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CHAPTER 1: INTRODUCTION  
Renal failure is a recognised important contributor to mortality as well as morbidity associated with 
HIV infection.  It can be directly related to HIV infection as in HIVAN, HIVIC, and HIV-associated 
thrombotic microangiopathy or it can be caused by complications of opportunistic infections, HIV-
associated diseases, as well as drugs used to manage HIV infection.  Furthermore, it can be caused by 
chronic diseases unrelated to HIV, such as diabetes, hypertension, and connective tissue diseases.  
HIV-associated chronic kidney disease (CKD) is particularly relevant for countries of sub-Saharan 
Africa (SSA) as they carry most of the global HIV burden. Epidemiological studies delineating a 
reliable prevalence rate of renal diseases in HIV-positive populations of SSA and South Africa are 
scarce. However, there is a general impression of a substantial population prevalence estimated at 
between 6% and 48.5% in SSA for the HIV-positive populations and 13.9% for the general 
populations [1-4]. 
 
1.1 HIV and renal disease 
Various kidney disease manifestations have been linked to direct viral infection namely HIVAN, 
HIVIC and thrombotic microangiopathy. These entities result from direct interaction with HIV or 
immune complex deposition and result in predominantly glomerular disease [5]. They were the 
predominant pathologies among HIV-positive patients biopsied in the pre-ART era [6].  HIVAN, in 
particular, was characterised by rapid progression towards ESRD contributing substantially towards 
end-stage renal failure associated with HIV [7].  The second group of HIV-related renal diseases 
results from opportunistic infections, HIV-associated diseases, and the drugs used to manage HIV 
itself or associated conditions. These include disseminated infections resulting in direct renal 
destruction as in renal tuberculosis and pyelonephritis, or severe infections resulting in septicaemia 
and ATN [8].Various drugs used in the control of HIV infection, such as tenofovir, and those used to 
treat opportunistic infections/associated conditions (such as rifampin, amphotericin B, Bactrim, etc.) 
can result in AIN, ATN, and other tubular dysfunction [5].  All these conditions are important causes 
of acute kidney injury and renal failure in HIV-afflicted individuals, and without prompt diagnosis 
and treatment can result in permanent chronic renal dysfunction. 
 
Introduction and widespread implementation of ART has improved outcomes associated with HIV 
and has turned this deadly disease into a chronic manageable condition.  With longer life expectancy 
risk factors typically associated with CKD in the general population such as diabetes, hypertension, 
race and other genetic factors, family history, and hepatitis become drivers of CKD in the HIV-
positive population as well.  Reports have documented an increased incidence of CKD in HIV-
positive patients of African ancestry in contrast to matched counterparts in the general population, and 
other race groups [9].  In the general population diabetes and hypertension account for 70% or more 
2 
 
of ESRD.  In US surveys these diseases are found to be more common in African American than in 
age-adjusted white Americans [9].  HIV infection itself has been associated with a many-fold increase 
in the risk of ESRD in African Americans with HIV compared to those without HIV, a risk similar to 
the diabetes-associated risk [5].  Other causes of kidney disease not directly linked to virus infection 
include classic FSGS, IgA nephropathy, AA-amyloidosis, lupus nephritis, membranous nephropathy 
and post-infectious glomerulonephritis.  All these non-HIV-related kidney diseases are likely to occur 
in the HIV population at rates approximating those of the general population [5]. 
 
1.1.1 HIV-associated nephropathy 
HIV-associated nephropathy and ESRD occurs almost exclusively among patients of African descent, 
due to genetic susceptibilities to both development and progression of these diseases [10, 11]. Studies 
have shown that host factors are important determinants of susceptibility of HIV patients to the 
development of CKD. African ancestry has been recognised as a significant factor closely associated 
with the development of several renal diseases. A study by Kopp et al. [12] showed a significant 
association between MYH9 genetic variation and development of idiopathic FSGS, HIV-associated 
FSGS, and hypertensive ESRD also collectively referred to as MYH9-associated nephropathies [12].  
Nelson et al. [13] identified two specific MYH9 gene variants (S-haplotype and F-haplotype) to have 
a very strong association to the MYH9-associated nephropathies, but no functional MYH9 gene 
mutation was identified [13].  Two APOL1 missense variants (termed G1 and G2 alleles) were 
subsequently identified to be more strongly associated with HIVAN and other MYH9-associated 
nephropathies than the previously reported leading MYH9 risk variants [14].  Furthermore, the 
APOL1 gene was neighbouring gene, located 14 kbp 3’ downstream from MYH9 and showed very 
strong linkage disequilibrium patterns with MYH9 variants. Both APOL1 variants are common in 
African chromosomes but absent in European chromosomes [14, 15].  In a biopsy series from HIV-
infected African-American patients, Fine et al. [16] demonstrated a strong association between APOL 
1 risk alleles and non-HIVAN FSGS as well as nearly three-fold higher risk for the development of 
ESRD in this population group. 
 
1.2 Treatment options 
As noted above, not only is HIV a direct cause of CKD but it can also complicate the clinical course 
of patients with ESRD due to other causes. In the pre-ART era, the survival of most patients with HIV 
infection and end-stage renal failure from whatever cause was dismal. In the presence of antiretroviral 
treatment, dialysis-requiring kidney failure can be managed with conventional methods used to 
manage ESRD in the general population. Treatment options range from haemodialysis and peritoneal 
dialysis to renal transplantation.  Studies have shown that kidney transplantation in a well-controlled 
HIV environment was not associated with increased infectious complications [11].  Well-controlled 
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HIV infection is regarded as undetectable HIV viral load and stable ARV therapy. Studies have also 
shown that survival of HIV-infected haemodialysis patients on ARV treatment was comparable to 
those of HIV negative and non-diabetic patients [17].  ARV treatment has been demonstrated to 
significantly increase survival rates of HIV seropositive haemodialysis patients. Factors associated 
with poor outcome include the following [17]: 
• Low CD4 counts 
• High viral loads 
• HIVAN as the cause of ESRD 
• Absence of ARV’s 
• Opportunistic infections. 
 
However, access to the full range of RRT options is a challenge for most patients in need in low- to 
middle-income countries such as those of SSA where HIV infection is also most prevalent. This lack 
of access is more heightened among the indigent who rely substantially on the state to satisfy their 
basic needs and among the HIV-positive patients who often are too ill to be prioritised in resource 
rationing. A 2015 review by Liyanage et al. [18] estimated that between 47% and 73% of patients 
requiring dialysis worldwide were unable to receive it. In this analysis, Africa was estimated to have 
the lowest RRT access at between 9% to 16%, reflecting a significant unmet need. The prevalence of 
RRT was noted to be around 80 pmp in Africa compared to 1840 pmp in North America according to 
2010 estimates. In South Africa, an overall RRT prevalence of 189 pmp has been reported recently 
consisting of 71.9 pmp in the public sector and 799.3 pmp in the private sector [19]. Although 
servicing about 84% of the South African population who are uninsured and poor, the public sector 
provided much less access compared to the private healthcare sector which services 16% of the 
population with healthcare insurance. These disparities in the provision of and access to RRT are 
typical of the difficulties faced by many low- to middle-income countries where indigent populations 
who rely on the state for most of their healthcare needs are too often unsatisfied due to the scarcity of 
resources. 
 
1.3 Peritoneal dialysis 
Peritoneal dialysis (PD) is a well-established form of dialysis used throughout the world [20].  Its’ 
main advantage is that it is relatively easy to teach, particularly important in the South African context 
as there is a large rural and semi-urban population with limited educational exposure.  Secondly, it is 
easy to travel with allowing for home dialysis therapy as it requires no complex machine.  It allows 
for a more liberal diet as well as fluid intake. It is premised on a principle of continuous fluid and 
solute removal allowing for a continuous steady-state biochemical and fluid status, and it avoids see-
saw fluctuations associated with intermittent haemodialysis [20].  It is also associated with 
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preservation of residual renal function, improved fluid and blood pressure control, reduced incidence 
of left ventricular hypertrophy, and less likelihood of severe cardiac arrhythmias [21]. 
 
1.3.1 Health economics of Peritoneal Dialysis 
PD has been suggested to be a potentially more cost-effective option compared to HD, readily 
implementable in low-resource settings as it requires less infrastructure and staff complement 
compared to HD and can be provided easier for patients living very far from dialysis centres [22-24]. 
However, health economic analysis studies have painted a more complex picture. In general, PD is 
found to be more economical than HD as reported by many analyses from Europe, North America, 
South America and Asia [22-26]. In Africa, only a handful of studies have attempted to do 
comparative economic analyses of PD vs HD [24-27]. Furthermore, meaningful review and 
comparison of countries involved have been compromised by varying methodologies and limited 
information provided on the inputs used to estimate costs [28]. These studies have reported mixed 
results with some African countries such as South Africa, Sudan, and Egypt reported to have very 
high PD to HD cost ratios at 1.72, 1.12 and 4.55, respectively, while countries such as Kenya and 
Senegal were reported to have more favourable PD to HD cost ratios at 0.75 and 0.72, respectively, 
comparable to western countries such as the UK and USA with cost ratios of 0.52 and 0.78, 
respectively [24, 25]. High costs of PD fluids which often are imported is the major factor frequently 
credited with driving PD to HD cost ratios unfavourably [29, 30]. Lack of trained health care workers 
and perceived higher infective complications associated with indigent populations are other factors 
which impede rapid PD growth in Africa. Conditions which have been associated with favourable PD 
growth are PD first policies, conducive government reimbursement and import tax policies, local PD 
fluid manufacturing and procurement, and investment in PD research, education and training [25].  
 
Under the right conditions, PD can potentially quickly upscale RRT access to those in desperate need. 
PD implementation requires far fewer resources and infrastructure costs compared with HD which is 
associated with very high start-up costs such as water purification systems and expensive HD 
machines. Furthermore, PD requires far fewer health care personnel and patient visits to maintain 
compared to in-centre HD which requires a lot more highly skilled health care personnel and frequent 
patient visits to the dialysis centre to be effective. Fewer clinic visits which can be once in one to four 
months, impose a far less burden on a typical CAPD patient compared to the recommended thrice 
weekly HD visits which can impose a tremendous financial and social burden on an indigent dialysis 
patient with limited resources. Socio-demographic factors, such as level of education, and availability 
of electricity, clean running water, and adequate sanitation system, have also been cited as hindrances 
to effective PD upscaling, but these factors also pose equally challenging problems to HD offerings 
[29]. The success of the PD first policies in Hong Kong and other parts of Asia in improving patient 
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survival and outcomes, such as prolonging residual kidney function, lowering infection risk, and 
increasing patient satisfaction, and in reducing the financial burden to the state typically posed by 
dialysis offerings highlights the potential of PD in expanding effective dialysis access [31, 32]. When 
considering all factors, the lower start-up costs, infrastructure requirements, health care personnel to 
patient ratios and socioeconomic demands on patients, PD seem to offer a more cost-effective option 
particularly for an indigent patient living far removed from a dialysis centre. 
 
1.3.2 CAPD in Africa 
Although CAPD offers great promise to increase access to RRT in the second most populous 
continent, that is also afflicted with enormous problems of poverty, and under development, its’ 
countries have failed to capitalize on this potential. CAPD prevalence is estimated to be less than 20 
pmp with some old estimates quoted as low as 2.2 pmp [25, 26]. Most of the continents CAPD 
offering is concentrated in South Africa with a prevalence rate of 26.2 pmp that is divided unequally 
between the public (20.9 pmp) and private (54.1 pmp) sectors [19]. Although estimated to contribute 
around 85% of the African PD population, the South African CAPD population only accounts for 
13.9% of people on RRT in the country [19, 26]. An inclination favouring HD over CAPD that is 
common across the continent. Some of the impediments that have been cited to hinder growth 
including economic considerations such as prohibitive costs of PD fluids that are often imported and 
transported across rudimentary or non-existent transport infrastructure and unfavourable government 
policies have been noted above. However, the few studies that have been published on outcomes of 
CAPD in AFRICA have not shown inferior outcomes, with one South African retrospective study 
reported patient survival of 86.7%, 78.7% and 65.3% at 1 year, 2 years and 5 years, respectively, and 
technique survival of 83.3%, 71.7% and 62.1%, respectively [33]. This study is notable as it was 
based in a poor rural province that was not serviced by a nephrologist but was able to achieve 
outcomes comparable with those of highly industrialised nations [34-37]. This shows the potential of 
CAPD in providing adequate RRT and acceptable outcomes in a setting of underdevelopment and 
poverty. However, peritonitis rates vary widely with some countries such as Egypt and Senegal 
previously reported rates of between 0.55-0.60/patient-years well below the ISPD recommended 
targets at the time [38-40]. Whereas other countries such as South Africa and Sudan have reported 
rates above those recommended by ISPD guidelines at 0.82-0.87/year [33, 41]. 
 
1.3.3 Complications of Peritoneal Dialysis 
There are several complications associated with the use of peritoneal dialysis system the major being 
infective, metabolic, nutritional and mechanical problems. Infective complications by far are the most 
important of all the complications, encompassing peritonitis, catheter exit infections, and tunnel 
infections. This complication depends on a delicate balance between colonisation of the PD system, 
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by organisms such as Staphylococcus aureus, and the local peritoneal defence mechanisms 
(chemotaxis, opsonisation, cytokine release). The main routes of infection are either through the 
catheter lumen resulting from touch contamination or through the outside of the catheter via exit site 
or tunnel contamination [20].  The other routes are through visceral micro-perforation as well as 
translocation of microorganisms from the intestinal lumen or urogenital organs to the peritoneal cavity 
[42].  This complication can in the majority of cases be managed without the need of withdrawing 
peritoneal dialysis, but it is also the most important complication leading to morbidity and change to 
haemodialysis [20].  
 
1.3.4 CAPD associated peritonitis 
Peritonitis in the setting of CAPD is defined by the presence of a cloudy PD effluent or abdominal 
pain and presence in PDE of more than 100 WBC/mm3 that has more than 50% polymorphonuclear 
cells or a positive culture in PDE [43, 44]. Rates vary widely from country to country and between 
units of individual countries from rates of about 0.82 episodes/patient-years to rates as low as 0.2 
episodes/patient-years published in some reports, reflecting a multiplicity of factors which contribute 
to the peritonitis risk [33-35, 45-47].  Gram-positive organisms account for the majority of cases of 
peritonitis, with Staphylococcus species found in about 36.8% of peritonitis episodes [43].  Gram-
negative peritonitis is associated with poorer outcome and higher mortality.  Pseudomonas, the most 
prominent member of this group, carries a very high mortality and is difficult to eradicate without 
removal of the catheter [48-50].  Furthermore, a small but significant group of peritonitis episodes are 
caused by fungal infections that are associated with poor outcomes and high mortality, as well as 
difficulty in eradication without removal of the catheter.  Culture-negative peritonitis, where a 
positive culture result is not obtained, account for a variable 10% to 30% of peritonitis and is 
frequently associated with culturing techniques employed for the PD effluent [43]. 
 
1.3.5 Risk factor for CAPD associated peritonitis 
Several factors have been associated with increased risk of developing peritonitis.  Technical factors 
have been long recognised contributors to the development of peritonitis.  Therefore, the 
developments of closed drainage systems such as the Y system and then the spikeless Ultra Twin bag 
system have significantly improved the incidence of peritonitis.  These systems based on flush before 
fill principle have enhanced PD infection prevention and management [20, 43]. 
 
Exit-site and tunnel tract as identified above are prime risk factors for the establishment and spread of 
infection to the abdomen. Typical infections afflicting these sites are Staphylococcus aureus and 
Pseudomonas aeruginosa [43, 44].  Exit-site infection is characterized by the presence of a purulent 
drainage, with or without associated peri-catheter skin erythema.  However, tunnel infection is 
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characterized by erythema, oedema, or tenderness over the subcutaneous pathway, and typically 
occurs in the presence of an exit-site infection but may occur alone. To prevent these infections 
aseptic techniques with nonirritating solutions and catheter immobilization are recommended by the 
Peritoneal Access Committee of the ISPD [43]. 
 
Antibiotic treatment is a risk factor for the development of multidrug resistant microorganisms and 
fungal peritonitis [43].  The latter being a serious complication associated with death in approximately 
25% to 40% of episodes and failure of CAPD technique [44, 51].  It is postulated that antibiotic 
therapy suppresses the normal bacterial flora of the intestine and induces an overgrowth of intestinal 
fungi, which in turn invade across the intestinal mucosal barrier to cause an infection in the peritoneal 
cavity [51]. 
 
Staphylococcus aureus nasal/skin carriage is a recognised risk factor for the development of ESIs and 
peritonitis.  A prospective cohort study by Luzar et al. [52] (1990) of 140 consecutive patients 
beginning CAPD at seven European hospitals enrolled over a year provided some evidence of a link 
between S. aureus nasal carriage and development of ESIs by the same organism.  In this study, 63 
patients (45%) were identified as S. aureus carriers due to a positive pre-CAPD culture of nasal 
swabs.  Staphylococcus aureus carrier group had a higher rate of ESI (0.4 episodes/patient-year) than 
among non-carriers (0.1 episodes/patient-year, p-value 0.012). The probability of remaining free of 
ESI at 18 months was 92% among non-carriers and 54% among carriers.  Staphylococcus aureus 
peritonitis was confined to carrier group while non-carriers had S. epidermis related peritonitis 
predominantly.  No S. aureus peritonitis was observed in the non-carrier group during the study 
period. The study showed that nasal cultures were sensitive and sufficient in determining at-risk 
patients [52].  Bernardini et al. [53] (1996) performed a prospective RCT comparing oral cyclical 
rifampin (n = 41) to daily application of mupirocin to the exit site (n = 41) as prophylaxis to prevent 
ESIs.  Both regimes were equally effective in reducing S. aureus PD-related infections (0.13 and 
0.15/dialysis-year at risk, mupirocin vs rifampin, p = NS) compared to prospectively collected prior 
rates without prophylaxis (0.46/dialysis-year at risk) [43, 53, 54]. 
 
Vychytil et al. [55] (1998) performed a prospective cohort study using 76 PD patients treated in one 
centre in Vienna, Austria, over a three-year period.  This study evaluated risk factors for the 
development of S. aureus nasal carriage and S. aureus catheter-related infection.  The 76 study 
subjects were allocated to three groups.  Group 1 consisted of 15 patients with diabetes.  Group 2 
consisted of 22 patients with chronic graft failure after renal transplantation who continued 
immunosuppression because of residual graft function.  Group 3 consisted of 39 patients without 
immunosuppression or diabetes mellitus.  The study results revealed a higher incidence of 
Staphylococcus aureus nasal carriage in the diabetic and immunosuppressed groups (73.3% and 
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72.7% respectively) compared to the non-diabetic and non-immunosuppressed group (59%).  
Staphylococcus aureus catheter infection rate was significantly higher in nasal carriers compared to 
non-carriers in all groups (0.71/year vs 0.41/year for group 1, 1.17/year vs 0.61/year for group 2, 
0.46/year vs 0.16/year for group 3). Staphylococcus aureus catheter-related infection rate of 
immunosuppressed non-nasal carriers was even higher than the infection rate of Staphylococcus 
aureus nasal carriers of non-diabetic non-immunosuppressed Group (0.61/yr vs 0.46/yr).  This result 
highlights the point that immunosuppression can independently escalate the risk of S. aureus-related 
infections in both S. aureus nasal carriers and non-carriers.  The probability of S. aureus peritonitis 
was found to be significantly higher in both diabetic and immunosuppressed groups [55].  From this 
study, inferences can be made about the effect of other immunosuppressive conditions, such as 
HIV/AIDS, on S. aureus nasal carriage and risk of catheter-related infection among CAPD patients as 
literature reports in this regard is scanty. 
 
1.4 CAPD and HIV infection 
Since HIV is an immunosuppressive state, with impairment of local defence mechanism as one of 
many challenges, it follows that the rate of peritonitis may be adversely affected in HIV-positive 
patients in particular among those with low CD4 counts and uncontrolled HIV infection. CAPD may 
also aggravate malnutrition and hypoalbuminaemia in this population especially among those with 
severe wasting syndrome [20].  The presence of protein and amino-acid losses in the dialysate is also 
thought to potentially exacerbate the occurrence of peritonitis in this group [56].  These factors have 
the potential of compounding the risk of morbidity and mortality of HIV-positive peritoneal dialysis 
patients.  
 
1.4.1 Outcomes of CAPD in HIV infection 
Few studies have examined the outcomes of CAPD in HIV-infected patients, and all have been 
retrospective studies with small sample sizes. However limited, these foundational studies have 
shown improvements in survival and infectious complications rates with the advent of ART [57].  A 
pre-ART era retrospective study by Tebben et al. [58] with a sample size of 39 HIV-infected CAPD 
patients showed very poor outcomes.  In this study, an overall peritonitis rate of 3.9 episodes/patient-
year was identified in the HIV-infected patients compared to a rate of 1.5 episodes/patient-year (P 
<0.001) among HIV-negative patients of the same unit.  Technical factors were some of the factors 
found to influence this rate with HIV-infected patients trained on the straight system having a 
significantly increased rate of peritonitis compared to those trained on the Y-disconnect systems (7.1 
vs 2.6 episodes/patient year, P < 0.00).  Furthermore, the one and two-year catheter survival rates 
were significantly reduced in the HIV-positive population (43% vs 68% at one year and 27% vs 50% 
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at two years).  This reduction was attributed to a high mortality rate among the HIV-positive CAPD 
population. 
 
Khana et al. [59] (2005) reviewed survival experience of 53 HIV-positive CAPD patients treated at 
Long Island College Hospital between 1987 and 2004 covering the transition period from pre-ART to 
the ART era.  In this retrospective study, HIV-positive CAPD patients tendered to be younger than 
their HIV-negative counterparts (41 years vs 56 years).  African-American race, diabetes, HIV 
infection, lower CD4 counts were found to be independent predictors of mortality.  Furthermore, 
HIV-positive patients had three times higher relative risk of mortality than HIV-negative patients, but 
survival depended very much on the clinical and immunologic stage of HIV infection.  Factors such 
as higher serum albumin, higher CD4 count, and HIV therapy were associated with reduced risk of 
mortality.  With each 1g/dl increase in serum albumin, there was an associated 43% reduction in 
relative risk of death.  CD4 counts above 200 were associated with a 90% reduction in the relative risk 
of death compared with those with CD4 counts less than 50 cells/mm3. The rates of hospitalization 
were significantly higher in HIV-positive patients than in HIV-negative patients (3.59 vs 1.63 
admissions/patient years).  The peritonitis rate was also found to be higher in HIV-positive population 
than in HIV-negative population (1.4 vs 0.84 episodes/patient years) [59]. 
 
Table 1: Survival and complication rates in different studies (Rivera et al.) [57] 
 
Table 1 above compares the survival data and complication rates of various studies done on HIV-
infected CAPD patients.  There has been a notable increase in life expectancy with survival on 
peritoneal dialysis of up to 9 years in some centres [57].  Mean survival rates have increased from 
rates between 10 to 17 months to rates above 40 months.  Complication rates have also improved over 
the years, with peritonitis rates in HIV CAPD patients decreased from a range between 2.4 to 3.9 
episodes/year in early studies to rates between 0.3 and 1.4 episodes/year in ART era studies.  These 
studies although limited by their retrospective nature highlight the improvements in outcomes of HIV-
positive CAPD patients with advances in the management of HIV infection and CAPD over the years. 
 
1.5 HIV shedding in PD fluid 
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The extent of HIV shedding in PD effluents and the kind of hazards PDE and exchange equipment 
potentially may pose to health workers and family members assisting or living with HIV-positive 
CAPD patients has not been fully explored.  An in-vitro experimental study by Farzadega et al. [60] 
(1996) assessed survival kinetics of HIV-1 in PDEs and PDET. In this study, HIV-1 was added to 
PDE and allowed to incubate at room temperature for 0 to 14 days.  HIV-1/PDE mixture was assessed 
for HIV-1 P24 antigen using special mononuclear cell co-culture medium.  High levels of HIV P24 
antigen were recovered up to 7 days of room temperature incubation.  The HIV/PDE mixture was also 
placed in PDET and incubated at room temperature for 10 minutes.  The solution was then removed, 
and PDET allowed to dry for up to 168 hours. At various drying time points, the tubing was flushed 
with HIV culture medium, and the culture supernatant was assayed for the HIV-1 P24 antigen.  HIV 
P24 antigen was recovered from PDET wash out up to 48 hours of drying time. Common disinfectants 
(Amukin and household bleach) solutions with varying dilutions were incubated with the HIV-1/PDE 
mixture for 10 minutes.  Amukin 50% and 10% household bleach solutions were found to be effective 
in killing HIV-1 particles in PDE [60]. This study demonstrated the survival of HIV-1 in PDE and 
PDET. However, there is a general lack of reports on the shedding of HIV-1 particles into PDE in the 
setting of ART. 
 
1.6 The South African HIV epidemic 
The earliest HIV infection cases in South Africa were identified during the 1980’s [61]. Three and 
half decades later the HIV epidemic still poses major challenges to the country's developmental 
potential.  In 2012, 6.4 million South Africans were estimated to be living with HIV comprising 
12.2% of the population, with some special groups such as black African females aged 20-34 and 
males aged 25-49 years reporting very high prevalence rates (31.6% and 25.7%, respectively) [62].  
The population level prevalence has also been reported to vary according to residential area type, 
being highest among informal urban and rural dwellers (19.9% and 13.4%, respectively). KwaZulu-
Natal has the highest estimated prevalence rate at 16.9% maintaining its status as the worst affected 
province in South Africa.  By 2009, an estimated 1.95 million orphans and 314000 deaths were 
reportedly attributed to AIDS [63].  Life expectancy had reduced from 67.4 years in 1990 to 49.2 
years in 2003 at the height of the HIV epidemic [64, 65].  From 2004 to 2011 when ARV treatment 
became available in the public sector, life expectancy increased to 60.5 years (2011), reflecting life 
gains due to improved ARV treatment penetration [65].  The HIV prevalence rate rose steadily from 
1990 but has been relatively stable since 2004, as evidenced by statistically non-differing HIV 
prevalence rates among pregnant women of between 29.1% and 29.7% [63, 66]. These indicators 
highlight the continued threat and overall magnitude of the HIV epidemic.  From all these statistics, 
we can deduce that advances have been made in impeding the HIV/AIDS epidemic, as demonstrated 
by the stabilisation of the infection rate and increased survival of those on ARV treatment.  However, 
there are still tremendous pressures imposed by its sheer magnitude. 
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The greatest challenge has come from pressures the epidemic has put on budgetary processes.  In 
2000, the department of health spent 676 million rands on HIV/AIDS programs, increasing to 3.3 
billion rands in 2007, further, increasing to 14,5 billion in the 2014/2015 financial year [61, 67]. 
These increases are mainly due to increased spending in laboratory services, ARV treatment expanded 
programs, nutritional programs, and general health system upgrades [61].  Improved laboratory 
services have been key in upscaling the availability of testing opportunities and in improving the 
clinical management of people affected by HIV/AIDS. The expanded ARV programme has prevented 
many deaths and has turned this deadly disease to a manageable chronic disease. In 2014, South 
Africa had 3.1 million people receiving ARV treatment, 47% of the number of individuals estimated 
to be living with HIV [67].  These statistics highlight the fact that while many lives have been affected 
and saved, but a considerable portion of people needing assistance have not yet been reached.  In 
2016, the South African government adopted the test-and-treat model advocated by WHO, thus 
eliminating the CD4 count threshold for accessing ART and greatly expanding the pool of HIV-
infected patients qualifying for the ARV programme [68]. 
 
1.7 Renal replacement options in South African 
It is now widely recommended that dialysis should not be withheld to patients based on their HIV 
serostatus alone. International experience has shown that HIV-positive patients can be dialyzable and 
transplantable [69].  However, in South Africa, renal replacement therapy (RRT) is not widely 
available due to limited resources. In the private sector, dialysis can be accessed if the patient can 
afford it or is on medical aid.  However, in the public sector dialysis is reserved for those meeting the 
criteria for the transplant programme [70].  
 
The criteria for renal dialysis and transplantation of HIV-positive patients in South Africa are: 
• “Stability on antiretroviral therapy (ART) for at least six months. 
• Adherence to ART is demonstrated, and there is a commitment to lifelong therapy. 
• Absence of current AIDS-defining illness” [70] 
 
Many patients in clinical practice present with severe dialysis-requiring renal failure at the same time 
they are diagnosed with HIV. In these instances, there is no time to wait for stabilisation on ARV 
treatment before initiating renal treatment. Without effective renal replacement treatment, these 
patients are condemned to uncomfortable and untimely death. The challenge is how to bridge the gap 
between dialysis-requiring renal failure presenting acutely before ART initiation and the stabilisation 
of HIV infection on ART, considering the resource constraints in the public sector. This study 
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evaluates the efficacy of using peritoneal dialysis in the management of HIV-positive patients in 
settings where HIV infection is being stabilized concurrently with the start of renal replacement. 
 
1.8 Rationale 
As noted above South Africa has several budgetary pressures impressing on the public purse.  Many 
important imperatives compete for limited available financial resources.  The HIV epidemic is a 
recognised strain on the county’s developmental and economic potential. Its’ large size and demands 
have challenged the budgetary processes of the last two decades.  Non-communicable diseases such as 
CKD which can potentially affect individuals of African descent disproportionately are other 
worrying threats to both the health and financial wellbeing of the country.  The links between HIV 
and renal disease also increase the complexities of challenges noted. 
 
KwaZulu-Natal along with other provinces face a major shortage of available dialysis slots.  Many 
patients are diagnosed with severe renal failure requiring dialysis, but not all can be accommodated in 
the available haemodialysis machines.  Limiting the eligibility for state funded dialysis to those 
qualifying for transplantation has not alleviated space constraints of the haemodialysis system.  Many 
patients in clinical practice are chronically under-dialyzed because the system cannot cope with a 
large number of patients accommodated by it.  HIV-associated renal failure can be expected to 
increase in prominence as identification and diagnoses of HIV-associated renal diseases improve, and 
as the ageing ART era HIV population develops chronic diseases due to increased survival.  Also, the 
inclusion of this population in the already overstretched dialysis system is a major challenge that 
needs innovative solutions to address it. 
 
CAPD has the prospect of being able to alleviate the pressures imposed on the haemodialysis system.  
It has the potential of decanting a substantial number of patients away from the overburdened 
haemodialysis circuit. This study examines its’ applicability and outcomes in an HIV end-stage renal 
failure population. 
 
1.9 Objectives 
1. To evaluate the effects of HIV positivity on outcomes of CAPD among dialysis-requiring 
renal failure patients. 
2. To evaluate the effects of HIV positivity on risk factors, pattern and incidence of peritonitis 
among peritoneal dialysis patients. 
3. To assess the effects of HIV positivity on the S. aureus nasal carriage and incidence of 
staphylococcal peritonitis and catheter-related infection among renal failure patients 
undergoing peritoneal dialysis. 
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4. To examine the presence and significance of HIV particles in peritoneal dialysis fluid in HIV-
positive patients treated with CAPD. 
 
1.10 Overview of Methodology 
1.10.1 Study design and sample population 
This prospective cohort study was carried out at KEH and IALCH, in Durban.  Seventy HIV-positive 
and 70 HIV-negative consecutive patients meeting the inclusion criteria were recruited between 
September 2012 and February 2015. Participants were followed monthly for 18 months or until end 
points of catheter removal or death. Each objective had a specific hypothesis guiding the methodology 
and specific outcomes that were observed and monitored monthly during follow-up (Table 2). 
Detailed methodology for each objective is outlined in chapters 2 to 5 describing specific research 
manuscripts. 
 
Table 2: Study design summary 
 Objective 1  Objective 2 Objective 3 Objective 4 
Hypothesis 
statement 
HIV increases the 
risk of catheter 
failure, morbidity, 
and mortality among 
renal failure patients 
undergoing 
peritoneal dialysis. 
HIV increases the 
risk of peritonitis 
complications 
among renal failure 
patients undergoing 
peritoneal dialysis 
HIV increases the 
risk of staphylococci 
species peritonitis 
and S. aureus nasal 
carriage thereby 
increasing the risk of 
S. aureus peritonitis 
and catheter 
infections among 
renal failure patients 
undergoing 
peritoneal dialysis 
HIV particles are 
present in the PD 
fluid in negligible 
amount and 
decrease even 
further with ARV 
treatment. 
Study 
type: 
Prospective cohort 
study 
Prospective cohort 
study 
Prospective cohort 
study 
Prospective cohort 
study 
Study 
population 
KEH and IALCH 
dialysis population 
KEH and IALCH 
dialysis population 
KEH and IALCH 
dialysis population 
HIV-positive 
CAPD patients 
Exposures HIV HIV HIV ART 
Risk 
factors 
1. CD4 count 
2. Viral load 
3. ART  
4. Diabetes 
1. CD4 count 
2. Viral load 
3. ART 
4. Diabetes 
1. CD4 count 
2. Viral load 
3. ART 
1. CD4 count 
2. Diabetes 
3. Malnutrition 
4. Peritonitis 
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 Objective 1  Objective 2 Objective 3 Objective 4 
5. Employment 
6. Level of education 
7. Race 
8. Malnutrition 
9. Type of residence 
5. Employment 
6. Level of 
education 
7. Malnutrition 
8. Race 
9. Type of 
residence 
5. Employment 
 
Outcomes 1. Catheter patency 
rate 
2. Survival/mortality 
3. First peritonitis 
event 
4. Hospitalisation rate 
5. Length of hospital 
stay 
1. All peritonitis 
events 
 
1. S. aureus nasal 
carriage 
2. S. aureus 
peritonitis 
3. Coagulase-negative 
staphylococci 
peritonitis 
4. Exit site infections 
5. Tunnel infections 
1. PD fluid HIV 
viral level 
2. Change in PDE 
viral level 
 
 
1.10.2 Inclusion Criteria 
Participants had to meet all the following inclusion criteria to be eligible for enrolment into the trial: 
i). Written informed consent obtained prior to the initiation of any study procedures; 
ii). Male or female subjects, younger than 60 years of age at the time informed consent is 
obtained;  
iii). Renal Failure - as evidenced by eGFR of less than 15 ml/min 
iv). Tenckhoff catheter inserted either at KEH or IALCH PD wards within two weeks before 
recruitment. 
 
1.10.3 Group stratification: 
Participants were stratified according to HIV infection status in into an HIV-positive group if ELISA 
positive or control (HIV-negative) if they were negative. Two 4th generation HIV ELISA tests 
performed by the NHLS were used to determine HIV infection status, screening using a HIV Ag/Ab 
Combo (CHIV) assay (ADVIA Centaur® XP, Siemens Healthcare Diagnostics, Tarrytown, NY, 
USA) and confirmation using HIV Combi and HIV Combi PT assays (Cobas e601, Roche 
Diagnostics, Mannheim, Germany). 
 
1.11 Overview of the Thesis 
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The thesis is divided into six chapters, including this one: 
 
Chapter 1: Outlines the background and the context of the study as well as the rationale, objectives 
and short overview of methodology. 
 
Chapter 2: (Published work) 
The paper entitled “CONTINUOUS AMBULATORY PERITONEAL DIALYSIS IN PATIENTS 
WITH HIV AND END-STAGE RENAL FAILURE” addresses objective 1 of section 1.11. It has 
been published in Peritoneal Dialysis International, the official journal of the International Society for 
Peritoneal Dialysis. It has been presented as published in the journal. 
 
Chapter 3: (Published work) 
The manuscript entitled “Peritonitis outcomes in patients with HIV and end-stage renal failure on 
peritoneal dialysis: A prospective cohort study” addresses objective 2 of section 1.11. It has been 
published in BMC Nephrology. It has been presented as published in the journal. 
 
Chapter 4: (Manuscript Submitted and under review) 
The manuscript entitled “Staphylococcal nasal colonisation and peritoneal dialysis infective 
outcomes in patients with HIV and end-stage renal failure: A prospective cohort study” 
addresses objective 3 of section 1.11. It has been submitted for publication in BMC infectious 
diseases and is under review. It has been presented in the format requested by the journal. 
 
Chapter 5: (Published work)  
The manuscript entitled “Detection of human immunodeficiency virus-1 ribonucleic acid in the 
peritoneal effluent of renal failure patients on highly active anti-retroviral therapy” addresses 
objective 4 of section 1.11. It has been published in Nephrology Dialysis Transplantation. It has been 
presented as published in the journal. 
 
Chapter 6: Provides a general discussion and conclusion as well as proposes future work and 
recommendations. 
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CHAPTER 2: CAPD OUTCOMES IN HIV PATIENTS 
Chapter 2 evaluates the effects of HIV-infection on outcomes of CAPD in end-stage renal failure 
patients requiring dialysis at one year. The outcomes of interest are catheter patency and failure, first 
peritonitis event, mortality, and hospital admissions. The paper entitled “CONTINUOUS 
AMBULATORY PERITONEAL DIALYSIS IN PATIENTS WITH HIV AND END-STAGE 
RENAL FAILURE” is presented as published in Peritoneal Dialysis International. 
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CHAPTER 3: CAPD PERITONITIS IN HIV PATIENTS 
Chapter 2 outlined the effects of HIV-infection on outcomes of CAPD in end-stage renal failure 
patients requiring dialysis. At one-year catheter patency and failure were not demonstrated to be 
adversely influenced. Nevertheless, uncontrolled HIV infection was associated with increased 
mortality, all-cause hospital admissions, and initial peritonitis risk. The first peritonitis rates were 
significantly increased in the HIV-positive cohort compared to the HIV-negative cohort. Chapter 3 
further explores the peritonitis risk and its’ influence on catheter failure outcomes at 18 months. It 
examines the effects of HIV infection on all peritonitis episodes, including relapses and other 
subsequent episodes. It assesses the overall peritonitis rate, microorganism patterns, and risk factors 
associated with adverse outcome in relation to HIV infection. Chapter 3 presents a paper entitled 
“Peritoneal dialysis peritonitis outcomes in patients with HIV and end-stage renal failure: A 
prospective cohort study” as published in BMC Nephrology. 
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CHAPTER 4: STAPHYLOCOCCUS IN HIV AND CAPD 
The early peritonitis risk associated with HIV outlined in Chapter 2 was further shown to extend 
beyond the initial peritonitis event in Chapter 3, as relapses and other subsequent peritonitis events 
were shown to be significantly higher in the HIV-positive cohort compared to the HIV-negative 
cohort. HIV infection was associated with increased overall peritonitis rates and the latter further 
modified by the immunological state of the infected patient. Furthermore, the gram-positive 
peritonitis rate was shown to be significantly higher in the HIV-positive cohort compared to the HIV-
negative cohort. Chapter 4 explores further by examining the effects of HIV infection on 
Staphylococcus peritonitis, the predominant gram-positive organisms associated with CAPD 
peritonitis. Moreover, the effects of HIV infection on Staphylococcus aureus nasal carriage and 
catheter infection rates in our CAPD cohort are assessed as they are prime risk factors associated with 
gram-positive peritonitis. Chapter 4 is presented in a manuscript format entitled “Staphylococcal 
nasal colonisation and peritoneal dialysis infective outcomes in patients with HIV and end-stage 
renal failure: A prospective cohort study” as submitted for publication in BMC infectious diseases 
and is currently under review. 
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ABSTRACT 
Background 
Staphylococcal infective complications can cause significant morbidity in human 
immunodeficiency virus (HIV)-positive patients undergoing dialysis. In poorly resourced 
regions, such as sub-Saharan Africa, where HIV is prevalent but access to renal replacement 
therapy is limited, continuous ambulatory peritoneal dialysis (CAPD) can be a cost-effective 
option. This study evaluated the effects of HIV infection on nasal carriage of Staphylococcus 
aureus, staphylococcal peritonitis, and catheter infection rates in patients with end-stage renal 
failure managed with CAPD. 
Methods 
Sixty HIV-positive and 59 HIV-negative CAPD patients were enrolled and were followed up 
for up to 18 months. Staphylococcus aureus nasal carriage (detected by nasal swab culture), 
Staphylococcal peritonitis (diagnosed by clinical presentation, CAPD effluent Staphylococcal 
culture, and white blood cell count ≥100 cells/µL), and catheter infections (including exit site 
and tunnel infections) were assessed monthly. Cox regression survival analysis was used to 
assess the risk factors for Staphylococcal infection. 
Results 
At 18 months, S. aureus nasal carriage rates were 43.3% and 30.5% (p = 0.147) and the 
methicillin-resistant S. aureus (MRSA) nasal carriage rates were 31.7% and 13.6% (p = 0.018) 
for the HIV-positive and HIV-negative cohorts, respectively. S. aureus peritonitis rates were 
similar in the HIV-positive and HIV-negative cohorts at 0.136 and 0.129 episodes/person-
years, respectively, (hazard ratio [HR] 0.96, 95% confidence interval [CI] 0.36–2.60, p = 
0.942). The HIV-positive cohort was associated with an increased coagulase-negative 
staphylococcal peritonitis rate compared with the HIV-negative cohort (0.435 vs. 0.089 
episodes/person-years; HR 5.27, 95% CI 2.13–13.04, p < 0.001). On multivariable analysis, 
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HIV (HR 3.35, 95% CI 1.20–9.36, p = 0.021) and diabetes (HR 3.95, 95% CI 1.18–13.30, p = 
0.026) were prominent independent predictors of staphylococcal peritonitis. S. aureus catheter 
infection rate in the HIV-positive cohort was higher among the S. aureus nasal carriers (0.302 
episodes/person-years) than the non-carriers (0.036 episodes/person-years) (HR 8.41, 95% CI 
1.03–68.74, p = 0.047). 
Conclusions 
These findings suggest that HIV infection may be a risk factor for MRSA nasal colonisation 
and it may increase the risks of coagulase-negative staphylococcal peritonitis and S. aureus 
catheter infections in association with S. aureus nasal carriage. 
 
KEY WORDS: Continuous ambulatory peritoneal dialysis (CAPD); HIV; peritonitis; 
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INTRODUCTION 
Infection is a major challenge in patients with end-stage renal failure who are managed 
with continuous ambulatory peritoneal dialysis (CAPD), and it is an important source of 
morbidity and technique failure. Gram-positive bacteria, most notably coagulase-negative 
staphylococci (CNS) and Staphylococcus aureus(S.aureus), frequently cause CAPD-
associated peritonitis [1-3]. Peritonitis caused by CNS infection tends to follow a benign 
clinical course that is easily treatable, while S. aureus peritonitis can be complicated with 
relapses and the need for catheter removal, particularly if it is associated with exit site or 
tunnel infections. These infections are commonly caused by touch contamination. An 
important risk factor for CAPD-associated exit site infections and peritonitis is S. aureus 
nasal carriage [4-6]. Immunosuppression, diabetes, previous antibiotic use, smoking, 
healthcare exposure, overcrowding, and intravenous drug abuse are among the factors that 
influence S. aureus colonisation [5, 7-10]. Carriage rates vary according to the geographical 
location, ethnicity, sex, and age [9]. Mupirocin and topical antibiotics have been associated 
with decreased S. aureus exit site infections, but not necessarily S. aureus peritonitis [11]. 
Staphylococcus aureus is a commonly isolated pathogen that causes significant morbidity 
and mortality among patients on dialysis, especially among those with indwelling catheters 
[12, 13]. The infections caused by S. aureus include pneumonia, bacteraemia, endocarditis, 
and skin and soft tissue infections. These infections present greater problems to 
immunocompromised patients, including those who are infected by the human 
immunodeficiency virus (HIV), than to those who are not immunocompromised, as 
immunocompromised patients are at an increased risk of infective complications caused by 
impaired host defence mechanisms [14-17]. An association between HIV infection and 
increased rates of S. aureus nasal colonisation in the general population has been reported, 
and increased likelihood of colonisation has been suggested in the advanced stages of HIV 
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infection [7, 18]. Infective complications in HIV-positive patients on dialysis can cause 
significant morbidity and mortality, and they can result in the need to transfer to 
haemodialysis, which gives rise to greater cost burdens to health budgets. In poorly resourced 
regions, such as sub-Saharan Africa, where HIV is extremely prevalent but access to renal 
replacement therapy is limited, CAPD can represent a cost-effective option. Indeed, CAPD 
can be implemented with relative ease and without the need for complex equipment, and it is 
well suited for areas that are remote or have limited dialysis facilities [19-21]. This study 
aimed to evaluate the effects of HIV infection on S. aureus nasal carriage, staphylococcal 
peritonitis, and catheter infection rates in patients with end-stage renal disease (ESRD) who 
were managed with CAPD. 
 
METHODS 
Study population 
This prospective sub-cohort of 129 patients was drawn from a 140-patient cohort 
recruited from King Edward VIII Hospital and Inkosi Albert Luthuli Central Hospital, 
Durban, South Africa, which has been described previously [16, 22]. Consecutive patients 
aged 18 to 60 years who required dialysis and had newly inserted double-cuffed coiled 
Tenckhoff catheters were recruited between September 2012 and February 2015. Sixty HIV-
positive and 59 HIV-negative patients who had at least one nasal swab sample taken during 
follow-up were included in this sub-study. The study protocol was approved by the 
University of KwaZulu-Natal Biomedical Research Ethics Committee (BE 187/11), and 
informed consent was obtained from the patients prior to enrolment. The status of HIV 
infection was determined by two 4th generation HIV enzyme-linked immunosorbent assays 
performed by the South African National Health Laboratory Service (NHLS) before 
enrolment; screening for HIV was performed using a HIV Ag/Ab Combo (CHIV) assay 
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(ADVIA Centaur® XP, Siemens Healthcare Diagnostics, Tarrytown, NY, USA) and 
confirmation was done using HIV Combi and HIV Combi PT assays (Cobas e601, Roche 
Diagnostics, Mannheim, Germany). Highly active antiretroviral therapy (HAART) was left to 
the discretion of the local clinic. 
Y-sets, twin-bag systems, and conventional peritoneal dialysis (PD) solutions (Dianeal® 
1.5%, 2.5%, or 4.25% dextrose, icodextrin, or amino acid-based solutions; Baxter Healthcare, 
Deerfield, IL, US) were used in all CAPD patients. They generally performed four exchanges 
per day. All patients received approximately 40 hours of practical and theoretical CAPD 
training in groups and individualised sessions conducted by the same nursing team of two 
senior nurses working together. A prophylactic intravenous antibiotic was administered to all 
patients prior to PD catheter insertion. Patients were prescribed 4% chlorhexidine Surgiscrub 
soap for hand washing and chlorhexidine 0.5% in ethanol 70% solution for hand rubs 
between hand washing. They were directed to use water and medicated soaps of their choice 
for exit site care. 
Enrolment and follow-up 
The patients’ demographic, clinical, and biochemical data were documented on enrolment. 
The patients were followed up monthly at a central renal clinic in Inkosi Albert Luthuli Central 
Hospital for 18 months or until the endpoints of catheter removal and subsequent transfer to 
haemodialysis or death. At each follow-up assessment, nasal swabs were taken, phlebotomy 
was performed for biochemical tests, and the details of infective complications and hospital 
admissions in the intervening periods were recorded on predefined questionnaires. Full blood 
counts were performed and the serum concentrations of C-reactive protein, urea, creatinine, 
electrolytes, albumin, and ferritin were measured at NHLS, and the results were periodically 
retrieved from the Inkosi Albert Luthuli Central Hospital’s electronic results database. 
Microbiology 
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Swabbing of the anterior nasal vestibules with sterile swabs (Amies Agar Gel-No Charcoal 
Transport System; Copan Italia SpA, Brescia, Italy) was performed monthly by a research 
nurse, and the swabs were transported to the laboratory for processing. Colistin-nalidixic agar 
and mannitol salt agar media were used for the cultures. The CAPD nurse took PD effluent 
specimens for white blood cell (WBC) counts and culture when the patients’ clinical 
presentations suggested peritonitis, and they were transported to the NHLS microbiology 
department in sterile specimen bottles for processing. The culturing was done on chocolate 
blood agar and brain-heart infusion broth. A Vitek® 2 system (bioMérieux, France) was used 
for species identification and antibiotic susceptibility testing of the nasal swab and PD effluent 
specimens. The PD effluent WBC counts were determined using a 40× microscope objective 
lens. 
Definitions 
A peritonitis episode was defined as a clinical presentation with a cloudy effluent or 
abdominal pain associated with a PD effluent WBC count of >100 cells/µL or a positive PD 
effluent culture. All patients were treated for at least two weeks, and they initially received 
intraperitoneal vancomycin and amikacin empirically, with further therapy modified 
according to the culture results. Episodes with culture-confirmed Staphylococcus growth and 
the date of presentation, information about whether the patient was treated as an inpatient or 
outpatient, and the presenting PD WBC counts were included in this analysis. The infection 
rates were calculated as the total number of infectious episodes with an organism during the 
follow-up period divided by the dialysis-years’ time at risk, and they were expressed as the 
number of episodes per year [23]. 
Exit site infections were diagnosed clinically and they were defined based on the presence 
of purulent drainage, with or without skin erythema, at the catheter-epidermal interface. 
Tunnel infections were diagnosed clinically or using sonographic studies, and they were 
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defined based on the presence of erythema, oedema, or tenderness over the subcutaneous 
pathway [23]. Both infection types were referred to as catheter infections. 
The participants were classified as S. aureus nasal carriers if at least one culture from the 
monthly nasal swabs was positive for S. aureus, and they were classified as non-carriers if 
none of the cultures from the monthly nasal swabs was positive for S. aureus during follow-
up. The S. aureus nasal carriers were further classified as intermittent S. aureus carriers if 
only one nasal culture was positive for S. aureus during follow-up or as persistent carriers if 
more than one monthly nasal culture was positive for S. aureus. 
Mupirocin exposure 
Exposure to mupirocin during the study was determined through evaluation of the electronic 
hospital database at the end of the study period for instances where mupirocin was dispensed 
during each patient’s follow-up period. The date of the first documented prescription of 
mupirocin and the number of months prescribed were recorded for individual patients.  
Statistical analysis 
The continuous variables are expressed as mean ± standard deviation (SD) or median and 
the interquartile range (IQR), and they were compared using Student's t-test or the Wilcoxon-
Mann-Whitney test, as appropriate. The proportions and categorical variables were compared 
using the chi-square test or Fisher’s exact test, as appropriate. The survival estimates were 
computed using the Kaplan-Meier method, and the log-rank test was used to compare the 
survival curves. Univariate Cox regression survival analysis was used to estimate the 
associations between HIV infection and S. aureus nasal carriage and the outcome variables. 
Multivariable Cox regression analysis was used to identify independent predictors of survival. 
All of the analyses were performed using Stata, version 13.1 (StataCorp LP, College Station, 
Texas, USA), and the significance level was set at p < 0.05.  
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RESULTS 
Patients’ characteristics 
The study population of 119 CAPD patients included 59 HIV-negative and 60 HIV-positive 
patients with a mean age of 38.8 years (SD = 11.6 years) and 36.2 years (SD = 9.2 years), 
respectively, (p = 0.168). Women comprised 40.7% of the HIV-negative and 58.3% of the 
HIV-positive cohorts (p = 0.054). People of African ethnicity comprised 100% of the HIV-
positive cohort and 84.8% of the HIV-negative cohort (p = 0.001). Fifty-two percent of the 
HIV-positive patients were either newly diagnosed with HIV or had recently been started on 
HAART, less than six months before Tenckhoff catheter insertion. Fifty-two percent of the 
HIV-positive patients had a suppressed viral load of <150 copies/mL, which was the hospital 
laboratory assay’s limit at the time of enrolment. While the median baseline viral load was 
4,229.5 copies/mL (IQR: 817–88,294.5 copies/mL) for the patients with detectable viral loads, 
the median fell below the detectable limit (IQR: <150–2,284.5 copies/mL) when the patients 
with undetectable viral loads were included. The characteristics of the study population are 
outlined in Table 1. 
 
TABLE 1: Baseline Characteristics of the Patients  
 
Study end points 
After 18 months, 64.4% (38/59) of the HIV-negative patients and 33.3% (20/60) of the 
HIV-positive patients were alive with patent catheters (p = 0.001). Twenty-two percent 
(13/59) of the HIV-negative patients and 25.0% (15/60) of the HIV-positive patients (p = 
0.703) had their Tenckhoff catheters removed because of malfunctions or infective 
complications, and 10.2% (6/59) of the HIV-negative patients and 36.7% (22/60) of the HIV-
positive patients had died (p = 0.001). One HIV-negative and two HIV-positive patients had 
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their Tenckhoff catheters removed because their renal functions improved. One HIV-negative 
patient underwent live related renal transplantation, and one HIV-positive participant left the 
study to undergo haemodialysis and was lost to follow-up.  
Staphylococcal nasal carriage 
Thirty percent (18/59) of the HIV-negative patients and 43.3% (26/60) of the HIV-
positive patients had detectable S. aureus in the nares (p = 0.147). The median time from 
Tenckhoff catheter insertion to the first S. aureus detection was 251 days (IQR: 97 – 377 
days) for the HIV-negative patients and 67.5 days (IQR: 41 – 131 days) for the HIV-positive 
patients (p = 0.002). Twenty percent (12/59) of the HIV-negative patients and 33.3% (20/60) 
of the HIV-positive patients were persistent S. aureus carriers (p = 0.110). Methicillin-
resistant S. aureus (MRSA) was found in 13.6% (8/59) of the HIV-negative patients and in 
31.7% (19/60) of the HIV-positive patients (p = 0.018). Coagulase-negative staphylococci 
was detectable in the nares of 69.5% (41/59) in the HIV-negative cohort and 43.3% (26/60) 
in the HIV-positive cohort (p = 0.004). Both S. aureus and CNS in the nares either 
concomitantly or interchangeably were detected in 13.6% (8/59) of the HIV-negative cohort 
and 11.7% (7/60) of the HIV-positive cohort (Table 2). 
 
TABLE 2: Patient Outcomes at 18 Months 
 
Staphylococcal peritonitis 
Staphylococcus spp. was cultured from 16 HIV-negative and 29 HIV-positive peritonitis 
episodes that occurred in 17.0% (10/59) of the HIV-negative and 28.3% (17/60) of the HIV-
positive patients. The HIV-positive cohort was associated with a higher staphylococcal 
peritonitis rate (0.569 episodes/person-years) compared with the HIV-negative cohort (0.223 
episodes/person-years) (hazard ratio [HR] 2.58, 95% confidence interval [CI] 1.37 – 4.85, p = 
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0.003). The staphylococcal peritonitis rate in HIV-positive patients who had baseline cluster 
of differentiation (CD) 4+ cell counts of <200 cells/µL was 0.973 episodes/person-years (HR 
4.44, 95% CI 1.45–13.58, p = 0.009), and this decreased to 0.530 episodes/person-years when 
the baseline CD4+ cell count was >350 cells/µL (HR 2.40, 95% CI 1.18–4.86, p = 0.015) 
(Table 3). The staphylococcal peritonitis-free survival rates at 18 months were 71.7% in the 
HIV-negative cohort and 40.8% in the HIV-positive cohort (p = 0.002) (Figure 1).  
 
TABLE 3: Incidence Rates and Cox Proportional Hazard Univariate Analysis 
 
Figure 1: — Staphylococcal peritonitis and human immunodeficiency virus infection status. 
HIV = human immunodeficiency virus. 
 
On multivariable analysis, HIV (HR 3.35, 95% CI 1.20–9.36, p = 0.021), diabetes, body 
mass index, and waist circumference were found to be independent predictors of 
Staphylococcus spp. peritonitis (Table 4). 
 
TABLE 4: Cox Proportional Hazard Univariate and Multivariate Analyses: Risk Factors vs. 
Staphylococcal Peritonitis 
 
Coagulase-negative staphylococci peritonitis rates were 0.089 episodes/person-years in 
the HIV-negative cohort and 0.401 episodes/person-years in the HIV-positive cohort (HR 4.80, 
CI 1.93–11.94, p = 0.001). The coagulase-negative staphylococci peritonitis rates were 0.259 
episodes/person-years among CNS nasal carriers and 0.172 episodes/person-years among non-
CNS nasal carriers (HR 1.45, 95% CI 0.64–3.32, p = 0.376). 
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Staphylococcus aureus was cultured in nine HIV-negative and seven HIV-positive 
peritonitis episodes. Four HIV-negative S. aureus peritonitis episodes and one HIV-positive 
S. aureus peritonitis episode preceded the detection of S. aureus nasal colonisation, and three 
HIV-negative and five HIV-positive S. aureus peritonitis episodes followed the detection of 
S. aureus nasal colonisation. Two HIV-negative S. aureus peritonitis episodes and one HIV-
positive S. aureus peritonitis episode occurred in patients who did not have S. aureus nasal 
colonisation during follow-up. Methicillin-sensitive S. aureus caused 43.8% (7/16) (HIV-
negative) and 10.3% (3/29) (HIV-positive) of staphylococcal peritonitis episodes (p = 0.021). 
All MRSA peritonitis episodes, comprising two in the HIV-negative cohort and four in the 
HIV-positive cohort, occurred in MRSA nasal carriers. The S. aureus peritonitis-free survival 
rates at 18 months were 83.7% in the HIV-negative cohort and 84.6% in the HIV-positive 
cohort (p = 0.942) (Figure 2). The S. aureus peritonitis rates were 0.270 episodes/person-
years in the S. aureus nasal carriers and 0.041 episodes/person-years in the non-S. aureus 
nasal carriers (HR 6.90, 95% CI 1.97–24.25, p = 0.003). The S. aureus peritonitis-free 
survival rates at 18 months were 68.6% in the S. aureus nasal carriers and 95.8% in the non-
S. aureus nasal carriers (p < 0.001) (Figure 3). 
 
Figure 2 — S. aureus peritonitis and human immunodeficiency virus infection status. HIV = 
human immunodeficiency virus 
 
Figure 3 — S. aureus peritonitis in relation to S. aureus nasal carriage. SA = Staphylococcus 
aureus.  
 
Exit site and tunnel infections 
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Ten catheter infection episodes occurred in the HIV-negative cohort and 14 catheter 
infection episodes occurred in the HIV-positive cohort in 15.2% (9/59) and 18.3% (11/60) of 
the patients, respectively. Staphylococcus aureus was cultured from the exit site pus swabs or 
tunnel abscess aspirates in five HIV-negative and eight HIV-positive catheter infection 
episodes. One HIV-negative S. aureus catheter infection episode and none of the HIV-
positive S. aureus catheter infection episodes preceded the detection of S. aureus nasal 
colonisation, and one HIV-negative S. aureus catheter infection episode and seven HIV-
positive S. aureus catheter infection episodes followed the detection of S. aureus nasal 
colonisation. Three HIV-negative S. aureus catheter infection episodes and one HIV-positive 
S. aureus catheter infection episode occurred in patients who were not positive for S. aureus 
nasal colonisation during follow-up. The S. aureus catheter infection rates were 0.076 
episodes/person-years in the HIV-negative cohort and 0.156 episodes/person-years in the 
HIV-positive cohort (HR 1.96, 95% CI 0.64–6.03, p = 0.240). The S. aureus catheter 
infection rates were 0.199 episodes/person-years for the S. aureus nasal carriers and 0.056 
episodes/person-years for the non-carriers (HR 3.61, 95% CI 1.11 – 11.73, p = 0.033). The S. 
aureus catheter infection rates in the HIV-positive cohort were 0.302 episodes/person-years 
in the S. aureus nasal carriers and 0.036 episodes/person-years in the non-carriers (HR 8.41, 
95% CI 1.03–68.74, p = 0.047) (Table 3). 
Mupirocin exposure 
Eighty-six percent (51/59) of the HIV-negative cohort had mupirocin ointment 
prescribed for exit site application compared to 60.0% (36/60) of the HIV-positive cohort (p 
= 0.001). Furthermore, mupirocin ointment was prescribed for a median 5 (2–9) months in 
the HIV-negative cohort compared to 3 (2–6.5) months in the HIV-positive cohort (p = 
0.140). Fourteen percent (8/59) of the HIV-negative cohort had mupirocin nasal spray 
prescribed during follow-up compared to 15.0% (9/60) in the HIV-positive cohort (p = 0.822) 
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DISCUSSION 
This prospective cohort study evaluated the effects of HIV infection on S. aureus nasal 
carriage and CAPD-associated staphylococcal infective outcomes in patients with ESRD who 
required dialysis. Our study failed to demonstrate significant differences with respect to S. 
aureus nasal colonisation, peritonitis, or catheter infection rates in relation to HIV infection. 
However, HIV infection was associated with significantly higher MRSA nasal carriage and 
staphylococcal peritonitis rates, and significantly enhanced the risk of S. aureus catheter 
infection in association with S. aureus nasal carriage.  
Staphylococcus aureus nasal carriage rates as high as 76% have been reported for 
different patient populations on PD [24, 25], which underscores the variable, but high, 
colonisation rates among patients undergoing dialysis. The S. aureus nasal carriage rate of 
43.3% in our HIV-positive cohort is within the wide range of rates from 20% to 63% that 
have been cited for different non-dialysis HIV-positive populations [7, 8, 26-31]. The 
difference between the HIV-positive cohort (43.3%) and HIV-negative cohort (30.5%) in 
relation to the S. aureus nasal carriage rate was not statistically significant (p = 0.147), which 
may reflect an underpowered sample size for this outcome. However, the interval between 
Tenckhoff catheter insertion and the first S. aureus nasal detection was significantly shorter 
in the HIV-positive cohort (67.5 days) than in the HIV-negative cohort (251 days) (p = 
0.002), which highlights the increased underlying risk associated with HIV infection in 
relation to S. aureus nasal colonisation. To the best of our knowledge, this is the first study to 
prospectively evaluate the effects of an HIV seropositive status on S. aureus nasal 
colonisation rates in ESRD patients on CAPD. Our findings showed that the MRSA nasal 
carriage rate in the HIV-positive cohort (31.7%) was significantly higher than that in the 
HIV-negative cohort (13.6%) (p = 0.018), and that it was much higher than the pooled 
MRSA nasal carriage rate estimate of 6.9% (95% CI 4.8–9.3) reported in a meta-analysis of 
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HIV-positive non-CAPD populations [32]. This highlights the increased risk of MRSA 
colonies in the nares associated with HIV infection, which raises concerns about the 
subsequent development of more serious MRSA infections in vulnerable CAPD populations. 
The six MRSA peritonitis episodes in this study only occurred in the MRSA carriers, which 
further emphasizes the risks associated with such colonisation. Furthermore, the significantly 
higher proportion of episodes of methicillin-sensitive S. aureus peritonitis in the HIV-
negative cohort (43.8%) than in the HIV-positive cohort (10.3%) (p = 0.021) highlights the 
relatively low burden of methicillin-resistant infections in the HIV-negative group. Infection 
with HIV has been positively linked to an increased risk of MRSA colonisation and 
subsequent infection in the general population [33-35]. Colonisation and infection by MRSA, 
which is commonly acquired through nosocomial contact, have also been associated with 
exposure to antibiotics, prior hospitalisation, illicit drug use, chronic skin disease, and risky 
lifestyle behaviours in the general population and using trimethoprim-sulfamethoxazole may 
confer protection from MRSA colonisation [34, 36]. Healthcare- and antibiotic-associated 
exposures may have increased the risk of MRSA colonisation in our CAPD cohorts. 
Community-associated acquisition could also have contributed to the earlier detection of 
MRSA colonisation in the HIV-positive cohort, as compared to the later detection of MRSA 
colonisation in the HIV-negative cohort (63 vs. 140.5 days after Tenckhoff catheter insertion, 
p = 0.008), which indicates a more traditional nosocomial-associated acquisition in the HIV-
negative cohort [37]. 
The HIV-positive cohort had a higher staphylococcal peritonitis rate than the HIV-
negative cohort (0.569 vs. 0.223 episodes/person-years; HR = 2.58, p = 0.003), because of the 
significantly increased CNS peritonitis incidence in the former compared with that in the 
latter (0.435 vs. 0.089 episodes/person-years; HR = 5.27, p < 0.001), which highlights the 
increased vulnerability of HIV-positive patients to touch contamination. This HIV-associated 
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risk changed with the immunological status. Compared with the HIV-negative patients, the 
HIV-positive patients with CD4+ cell counts <200 cells/µL had a higher risk of contracting 
staphylococcal peritonitis (0.973 episodes/person-years; HR 4.44, p = 0.009) relative to the 
risk of those with CD4+ cell counts >350 cells/µL contracting staphylococcal peritonitis, 
which was lower (0.530 episodes/person-years; HR 2.40, p = 0.015), and this most likely 
reflects an impaired local immunity [38]. Coagulase-negative staphylococci is a common skin 
commensal found in many parts of the body (nose, axilla, groin, etc.) to various degrees [39, 
40]. It is also the most commonly isolated pathogen causing peritonitis in patients on CAPD 
[41]. Factors associated with the development of CNS peritonitis are access to the peritoneum 
via the catheter, bacterial characteristics allowing evasion of host defences, immune 
depression induced by conventional PD fluids, and inherent host immune system dysfunction 
[38, 39, 42]. In this study, HIV was found to increase the risk of developing CNS peritonitis, 
reflecting the immunosuppressive state of HIV and resultant impaired ability of local 
peritoneal immune defence mechanisms to combat the contaminating CNS organisms. 
Furthermore, CNS nasal carriage was found to be significantly increased in the HIV-negative 
cohort compared to that in the HIV-positive cohort (69.5% vs. 43.3%, p = 0.004), suggesting 
HIV-associated changes to the typical body commensal patterns favouring organisms such as 
MRSA, which are associated with greater healthcare exposure. However, CNS nasal carriage 
was not significantly associated with CNS peritonitis (HR 1.45, p = 0.376). Previous reports 
have also shown a disconnect between CNS strains colonising the body and those causing 
infection, as peritonitis-cultured strains tended to differ from those isolated from other body 
sites before infection [39, 40]. Documented mupirocin exit site exposure was significantly 
higher in the HIV-negative cohort than in the HIV-positive cohort (86.4% vs. 60.0%, p = 
0.001) due to earlier recruitment of a greater proportion of HIV-negative patients when 
hospital policy favoured routine mupirocin exit site prophylaxis. However, chronicled 
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mupirocin ointment exit site exposure was not shown to have meaningful influence on the 
incidence of staphylococcal peritonitis both on univariate and multivariable Cox analysis 
(univariate HR 1.13, p = 0.738; multivariate HR 2.51, p = 0.088). 
On multivariable analysis, HIV and diabetes were prominent independent predictors for 
the development of staphylococcal peritonitis, reinforcing the suggested risks attributed to 
impaired immunity. However, both cohorts responded well to the treatment, with 93.8% of 
the HIV-negative and 96.6% of the HIV-positive episodes of peritonitis responding to the 
treatment, which allowed CAPD to continue. The favourable treatment outcomes compare 
well with those described in previously published reports, because CNS peritonitis has a more 
benign course [1, 3, 43]. The S. aureus peritonitis rate was not affected by HIV infection 
status (HR 0.96, p = 0.942), an effect that may have been attenuated by the sporadic use of 
mupirocin prophylaxis that was intermittently available to the treating physicians. However, 
the S. aureus peritonitis rates were higher in both cohorts than those reported in the literature 
[44, 45], which probably reflects a higher intrinsic risk in our population which included 
patients who were poor, had low levels of secondary education, and had fewer available 
choices for alternative haemodialysis [46].  
Compared with the HIV-negative state, HIV infection was associated with higher all-
cause (0.160 vs. 0.286 episodes/person-years, HR 1.72, p = 0.190) and S. aureus (0.076 vs. 
0.156 episodes/person-years, HR 1.96, p = 0.240) catheter infection rates. These differences 
were not statistically significant, which was probably a consequence of the lower numbers of 
these outcomes. The study’s protocol did not restrict the use of mupirocin prophylaxis, either 
at the exit sites or the nares for ethical reasons, because these prophylactic measures 
significantly reduce S. aureus-associated catheter infections [11]. However, mupirocin was 
not uniformly used by the treating physicians. Concerns of resistance led to mupirocin being 
withdrawn from use in general CAPD by the hospital’s therapeutics committee midway 
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through the study period, and it was reserved for nasal decolonisation of S. aureus thereafter. 
Nevertheless, the sporadic use of mupirocin likely suppressed the incidence of exit site and 
tunnel infections. In the HIV-positive cohort, S. aureus nasal carriage was associated with a 
very high S. aureus catheter infection rate compared with the non-carriers (0.302 vs. 0.036 
episodes/person-years, HR 8.41, p = 0.047), which highlights an enhanced risk of this 
outcome among HIV-positive S. aureus nasal carriers. Seven of eight episodes of S. aureus 
catheter infection were preceded by S. aureus nasal colonisation, and only one episode 
occurred in a non-carrier, which stresses the importance of the influence of S. aureus nasal 
colonisation on catheter infection risk. 
The main limitation of our study is that it was a single-centre observational study, which 
limits the causation inferences that can be drawn. The sample size may have been too small 
for differences in the S. aureus nasal colonisation and catheter infection outcomes to be fully 
appreciated. Furthermore, the disproportionately higher mortality rate in the HIV-positive 
cohort contributed to a significantly higher dropout rate and a significantly shorter 
observation time compared to the HIV-negative cohort. This may have resulted in 
underestimation of peritonitis and catheter-associated infection rates in the HIV-positive 
cohort. However, it is not expected to have meaningfully altered observed associations, such 
as the CNS peritonitis risk associated with HIV, as this kind of potential bias is expected to 
have underestimated these associations rather than enhance them. The observed differences in 
the S. aureus nasal colonisation and infection rates require further investigation with 
additional research in prophylactic measures. 
CONCLUSIONS 
This study’s findings suggest that HIV infection adversely influences S. aureus nasal 
colonisation, particularly colonisation by MRSA, and that it may increase the risk of CNS 
peritonitis. Differences in the S. aureus peritonitis and catheter infection rates in relation to 
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HIV infection were not significant. However, HIV infection may enhance the risk of S. 
aureus catheter infections that are associated with S. aureus nasal carriage. These 
observations contribute to our understanding of the resistance profiles of S. aureus colonisers 
and the staphylococcal organism patterns that are likely to cause infection, which may assist 
in guiding appropriate antibiotic therapy and prophylaxis. 
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FIGURE LEGENDS 
Figure 1— Staphylococcal peritonitis according to human immunodeficiency virus infection 
status. 
HIV = human immunodeficiency virus. 
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Figure 2— S. aureus peritonitis according to human immunodeficiency virus infection status. 
HIV = human immunodeficiency virus 
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Figure 3— S. aureus peritonitis in relation to S. aureus nasal carriage. 
SA = Staphylococcus aureus.  
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TABLES 
TABLE 1: Baseline Characteristics of the Patients 
 
HIV negative  
(n = 59) 
HIV positive 
(n = 60) 
p value 
Mean ± SD age, years 38.8 ± 11.6 36.2 ± 9.2 0.168a 
Mean ± SD weight, kg  68.6 ± 12.3 65.4 ± 13.6 0.181a 
Body mass index, median (IQR) 23.8 (21.8–
28.4) 
22.8 (20.7–
27.9) 
0.239d 
Mean ± SD waist circumference, cm  90.4 ± 10.4 89.6 ± 11.5 0.703a 
Sex    
Female, n (%) 24 (40.7) 35 (58.3) 0.054b 
Race    
African, n (%)  50 (84.8) 60 (100.0) 0.001c 
Indian, n (%) 7 (11.9) 0 (0.0) 
Mixed race, n (%) 2 (3.4) 0 (0.0) 
Hypertension, n (%) 54 (91.5) 52 (75.0) 0.026c 
Diabetes, n (%) 3 (5.1) 6 (10.0) 0.491c 
SLE, n (%) 3 (5.1) 1 (1.7) 0.364 c 
Hepatitis B, n (%) 6 (10.2) 6 (10.0) 0.974b 
Primary residence    
Rural, n (%) 20 (33.9) 21 (35) 0.847b 
Urban, n (%) 39 (66.1) 38 (63.3) 
Education level    
Primary school, n (%)  15 (25.4) 11 (18.6) 0.649b 
High school, n (%) 26 (44.1) 27 (45.8) 
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HIV negative  
(n = 59) 
HIV positive 
(n = 60) 
p value 
Post-grade 12, n (%) 18 (30.5) 21 (35.6) 
Employment status    
Unemployed, n (%) 43 (72.88) 47 (78.3) 0.387b 
Employed, n (%) 16 (27.1) 12 (20.0) 
Tenckhoff catheter insertion method    
Laparoscopic, n (%) 57 (96.6) 31 (51.7) <0.001c 
Percutaneous, n (%) 2 (3.4) 29 (48.3) 
Haemoglobin (g/dL), median (IQR) 9.45 (8.2–
11.2) 
8.95 (7.8–9.8) 0.038d 
Mean ± SD albumin, g/L 35.5 ± 6.8 31.06 ± 6.8 0.002a 
eGFR (mL/min/1.73 m2), median (IQR) 6 (4–9) 6 (5–8) 0.940 d 
Creatinine (µmol/L), median (IQR) 728 (529–
1004) 
710.5 (592–
880) 
0.941d 
CRP (mg/L), median (IQR) 18 (6–34) 48.5 (18.5–
102.5) 
<0.001d 
ESR (mm/hr), median (IQR) 48 (29–61) 88 (50–129) <0.001d 
Ferritin (µg/L), median (IQR) 626 (335–
1047) 
565 (378.5–
905.5) 
0.770d 
CD4+ cell count    
Mean ± SD cells/µL 
 
407.8 ± 238.6 
 
CD4+ <200 cells/µL, n (%)  9 (15.0)  
CD4+ 200–350 cells/µL, n (%)  18 (30.0) 
CD4+ 350–500 cells/µL, n (%)  18 (30.0) 
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HIV negative  
(n = 59) 
HIV positive 
(n = 60) 
p value 
CD4+ ≥500 cells/µL, n (%)  15 (25.0) 
Viral load    
Median, copies/mL (IQR) 
 
4,229.5 (817–
88,294.5) 
 
Suppressed (<150 copies/mL), n (%)  31 (51.7) 
 
150–1,000 copies/mL, n (%)  8 (13.3) 
>1,000 copies/mL, n (%)  21 (35.0)  
HAART history at enrolment   
<6 months, n (%) 
 
31 (51.7) 
 
6–12 months, n (%) 
 
8 (13.3) 
>1 year, n (%) 
 
21 (35.0) 
HAART drug regimen    
3TC/EFV/ABC, n (%) 
 
50 (83.3) 
 
3TC/EFV/AZT, n (%) 
 
2 (3.3) 
3TC/EFV/D4T, n (%) 
 
3 (5.0) 
3TC/NVP/ABC, n (%) 
 
3 (5.0) 
Alluvia/ABC/3TC, n (%) 
 
1 (1.7) 
AZT/3TC/aluvia, n (%)  1 (1.7)  
SD = standard deviation; IQR = interquartile range; HIV = human immunodeficiency virus; 
CD = cluster of differentiation; SLE = systemic lupus erythematosus; eGFR = estimated 
glomerular filtration rate (Modification of Diet in Renal Disease equation); HAART = highly 
active antiretroviral therapy; ESR = erythrocyte sedimentation rate; 3TC = lamivudine; EFV 
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= efavirenz; ABC = abacavir; AZT = zidovudine; D4T = stavudine; NVP = nevirapine; CRP 
= C-reactive protein.  
at-test for comparison of means; bPearson’s χ2 test; cFisher's exact test; dWilcoxon-Mann-
Whitney test. 
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TABLE 2: Patient Outcomes at 18 Months 
 HIV negative HIV positive p value 
Staphylococcus aureus nasal 
carriage 
30.5% (18/59) 43.3% (26/60) 0.147a 
 
Intermittent S. aureus carrier 10.2% (6/59) 10.0% (6/60) 0.976a 
Persistent S. aureus carrier 20.3% (12/59) 33.3% (20/60) 0.110a 
Time to first S. aureus nasal 
detection (days), median 
(IQR) 
251 (97–377) 67.5 (41–131) 0.002c 
MRSA nasal carriage 13.6% (8/59) 31.7% (19/60) 0.018a 
Time to first MRSA nasal 
detection (days), median 
(IQR) 
140.5 (97–
317.5) 
63 (31–80) 0.008c 
    
Coagulase-negative staphylococcal 
nasal carriage 
69.5% (41/59) 43.3% (26/60) 0.004a 
Dual carriage 13.6% (8/59) 11.7% (7/60) 0.756a 
    
Mupirocin exit site exposure 86.4% (51/59) 60.0% (36/60) 0.001 
Mupirocin exit site prescribed 
months, median (IQR) 
5 (2–9) 3 (2–6.5) 0.140 
Mupirocin nasal exposure 13.6% (8/59) 15.0% (9/60) 0.822 
Mupirocin nasal prescribed months, 
median (IQR) 
1 (1–2) 1 (1–3) 0.472 
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 HIV negative HIV positive p value 
Staphylococcal peritonitis episodes, 
n (n excluding relapsed) 
16 (15) 29 (28) 0.046a 
MSSA 43.8% (7/16) 10.3% (3/29) 0.021b 
MRSA 12.5% (2/16) 13.8% (4/29) 1.000b 
MSCNS 37.5% (6/16) 48.3% (14/29) 0.486a 
MRCNS 6.3%(1/16) 27.6% (8/29) 0.127b 
Time to peritonitis episode 
(days), median (IQR) 
213 (67–498.5) 214 (102–357) 0.776c 
PD WBC count (cells/µL), 
median (IQR) 
734 (256–2,500) 988 (430–3,420) 0.366c 
Outpatient treatment 56.2% (9/16) 58.6% (17/29) 0.878a 
Inpatient treatment 43.8% (7/16) 41.4% (12/29) 
Inpatient stay (days), median 
(IQR) 
10 (4–12) 10 (7–22) 0.419c 
Episode outcome    
Continuation of PD 93.8% (15/16) 96.6% (28/29) 0.590b 
Catheter removal 6.2% (1/16) 0 
Mortality 0 3.4% (1/29) 
    
Culture negative peritonitis 
episodes, n (n excluding relapsed) 
10 (9) 27 (24) 0.009a 
Time to peritonitis episode 
(days), median (IQR) 
212 (106 – 370) 143 (49 – 323) 0.432c 
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 HIV negative HIV positive p value 
All-cause catheter infection, n 
episodes (n patients) 
10 (9) 14 (11) 0.653a 
Time to all-cause catheter 
infection (days), median 
(IQR) 
112.5 (55–244) 180.5 (48–399) 0.429c 
Exit site infection, n episodes 
(n patients) 
9 (9) 10 (8) 0.358b 
Tunnel infections, n episodes 
(n patients) 
1 (1) 4 (3) 
S. aureus catheter infection, n 
episodes (n patients) 
5 (4) 8(7) 1.000b 
Time to S. aureus catheter 
infection (days), median 
(IQR) 
55 (41–107) 233 (93.5–427.5) 0.092 
S. aureus exit site infection, n 
episodes (n patients) 
4 (4) 5 (4) 1.000b 
S. aureus tunnel infections, n 
episodes (n patients) 
1 (1) 3 (2)  
HIV = human immunodeficiency virus; IQR = interquartile range; MSSA = methicillin-
sensitive Staphylococcus aureus; MRSA = methicillin-resistant Staphylococcus aureus; 
MSCNS = methicillin-sensitive coagulase-negative staphylococci; MRCNS = methicillin-
resistant coagulase-negative staphylococci; PD = peritoneal dialysis; WBC = white blood 
cell. 
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aPearson’s χ2 test; bFisher's exact test; cWilcoxon rank-sum (Mann-Whitney) test; dperitonitis 
episode count excluding peritonitis relapse. 
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TABLE 3: Incidence Rates and Cox Proportional Hazard Univariate Analysis 
Rates - episodes/person-years HIV negative  HIV positive  HR (95% CI) p value 
Staphylococcal peritonitis 0.223 0.569 2.58 (1.37–4.85) 0.003 
CD4+ <200 cells/µL  0.973 4.44 (1.45–13.58) 0.009a 
CD4+ 200–350 cells/µL  0.536 2.47 (1.04–5.85) 0.039a 
CD4+ ≥350 cells/µL  0.530 2.40 (1.18–4.86) 0.015a 
S. aureus peritonitis 0.129 0.136 0.96 (0.36–2.60) 0.942 
S. aureus nasal carriers 0.284 0.256 0.81 (0.27–2.42) 0.703 
7.00 (1.45–33.78) 0.015b 
Non-carriers 0.044 0.036 0.67 (0.06–7.38) 0.742 
7.32 (0.88–60.85) 0.065c 
     
CNS peritonitis 0.089 0.401 4.80 (1.93–11.94) 0.001 
CNS nasal carriers 0.109 0.504 4.73 (1.70–13.16) 0.003 
2.50 (0.29–21.47) 0.402d 
Non-CNS carriers 0.046 0.285 6.21 (0.76–50.77) 0.088 
1.58 (0.63–3.92) 0.327e 
     
All-cause catheter infection 0.160 0.286 1.72 (0.76–3.90) 0.190 
S. aureus catheter infection 0.076 0.156 1.96 (0.64–6.03) 0.240 
S. aureus nasal carriers 0.090 0.302 3.44 (0.70–16.93) 0.129 
1.58 (0.26–9.48) 0.615b 
Non-carriers 0.068 0.036 0.46 (0.05–4.41) 0.499 
8.41 (1.03–68.74) 0.047c 
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CI = confidence interval; HIV = human immunodeficiency virus; HR = hazard ratio; CD = 
cluster of differentiation; IRR = incidence rate ratio; CNS = coagulase-negative 
staphylococci. 
aHIV-negative group used as the reference group; bStaphylococcus aureus nasal carriers vs 
non-carriers in the HIV-negative cohort; cS. aureus nasal carriers vs non-carriers in the HIV-
positive cohort; dCoagulase-negative staphylococci nasal carriers vs non-carriers in the HIV-
negative cohort; eCoagulase-negative staphylococci nasal carriers vs non-carriers in the HIV-
positive cohort. 
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TABLE 4: Cox Proportional Hazard Univariate and Multivariate Analyses: Risk Factors vs. 
Staphylococcal Peritonitis 
 
Univariate Cox proportional 
hazards  
 
Multivariable Cox 
proportional hazardsa  
Variable HR (95%CI) P value   HR (95% CI) P value 
HIV 2.58 (1.37–4.85) 0.003 
 
3.35 (1.20–9.36) 0.021 
Age 0.99 (0.96–1.02) 0.480 
 
0.98 (0.93–1.03) 0.496 
Catheter insertion 
method 
1.52 (0.78–2.97) 0.219 
 
0.34 (0.06–1.86) 0.214 
Catheter insertion 
site 
2.34 (1.15–4.78) 0.019 
 
3.80 (0.57–25.48) 0.169 
Staphylococcal nasal 
carriage 
2.83 (0.68–11.75) 0.152 
 
5.88 (0.99–34.84) 0.051 
Staphylococcal 
catheter infection 
0.75 (0.23–2.44) 0.638 
 
0.40 (0.10–1.68) 0.213 
Mupirocin ointment 
exit site exposure 
1.13 (0.54–2.36) 0.738 
 
2.51 (0.87–7.25) 0.088 
Mupirocin nasal 
spray exposure 
2.41 (1.27–4.57) 0.007 
 
2.08 (0.85–5.08) 0.109 
Diabetes 2.80 (1.25–6.30) 0.013 
 
3.95 (1.18–13.30) 0.026 
Body mass index 0.94 (0.87–1.01) 0.108 
 
0.80 (0.69–0.92) 0.002 
Waist circumference 1.01 (0.98–1.05) 0.399 
 
1.12 (1.05–1.21) 0.001 
Baseline albumin 0.96 (0.91–1.00) 0.062 
 
0.98 (0.92–1.04) 0.445 
      
Baseline CD4 count 
     
HIV-negative Reference 
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Univariate Cox proportional 
hazards  
 
Multivariable Cox 
proportional hazardsa  
Variable HR (95%CI) P value   HR (95% CI) P value 
CD4 <200 4.44 (1.45–13.58) 0.009 
 
2.39 (0.53–10.89) 0.259 
CD4 200–350 2.47 (1.04–5.85) 0.039 
 
0.67 (0.20–2.26) 0.516 
CD4 >= 350 2.40 (1.18–4.86) 0.015   1   
BMI, Body mass index; CI, Confidence interval; CD = cluster of differentiation; HR, Hazard 
ratio; HIV, human immunodeficiency virus. 
aAdjusted for age, race, gender, smoking, diabetes, body mass index, waist circumference, 
baseline serum albumin, primary residence, highest education level, employment, baseline 
CD4 count, Tenckhoff catheter insertion site, Tenckhoff catheter insertion method 
(laparoscopic vs. percutaneous), staphylococci species nasal carriage, staphylococci species 
catheter infection, mupirocin nasal spray exposure, and exposure to topical mupirocin at exit 
site. 
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CHAPTER 5: HIV-1 IN PERITONEAL DIALYSIS EFFLUENTS 
Chapters 2-4 have shown uncontrolled HIV-infection to be a significant factor for adverse mortality 
and morbidity outcomes. Central to this theme is peritonitis which was significantly associated with 
HIV infection. This HIV-associated peritonitis risk was shown to be dependent on virologic control 
and immunological state of the HIV-positive incident CAPD patient. Chapter 5 examines the factors 
associated with poor virological control, manifested by detectable plasma HIV-1 viral load, as well as 
evaluates the shedding of HIV particles in CAPD effluents in an HIV-positive ESRD cohort on 
HAART. Chapter 5 is presented in a manuscript format entitled “Detection of human 
immunodeficiency virus-1 ribonucleic acid in the peritoneal effluent of renal failure patients on 
highly active anti-retroviral therapy” as submitted and accepted for publication in Nephrology 
Dialysis Transplantation. 
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Supplementary Table 5. 1: Detection of HIV-1 RNA in Plasma and CAPD effluents 
  Batch 1  
(N = 58) 
Batch 2  
(N = 38) 
Batch 3  
(N = 30) 
P value 
PD fluid HIV-1 viral load, <20 
copies/mL 
47 (81.0%) 28 (73.7%) 24 (80.0%) 0.668a 
PD fluid HIV-1 viral load, 20–
199 copies/mL 
3 (5.2%) 4 (10.5%) 2 (6.7%)  
PD fluid HIV-1 viral load, 200–
1000 copies/mL 
5 (8.6%) 5 (13.2%) 2 (6.7%)  
PD fluid HIV-1 viral load, >1000 
copies/ml 
3 (5.2%) 1 (2.6%) 2 (6.7%)  
     
Plasma fluid HIV-1 viral load, 
<20 copies/mL 
27 (46.6%) 19 (50.0%) 20 (66.7%) 0.196a 
Plasma fluid HIV-1 viral load, 
20–199 copies/mL 
5 (8.6%) 6 (15.8%) 3 (10.0%)  
Plasma fluid HIV-1 viral load, 
200–1000 copies/mL 
11 (19.0%) 6 (15.8%) 2 (6.7%)  
Plasma fluid HIV-1 viral load, 
>1000 copies/mL 
15 (25.9%) 7 (18.4%) 5 (16.7%)  
     
Virologic reboundb     
PD fluid  8 (21.0%) 5 (16.7%) 0.761a 
Plasma  8 (21.0%) 3 (10.0%) 0.323a 
Failure to suppressc     
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  Batch 1  
(N = 58) 
Batch 2  
(N = 38) 
Batch 3  
(N = 30) 
P value 
PD fluid  2 (5.3%) 1 (3.3%) 1.00a 
Plasma  11 (29.0%) 7 (23.3%) 0.783a 
PD, Peritoneal dialysis 
aFisher's exact test 
bVirologic rebound – HIV-1 viral load undetectable (<20 copies/mL) in batch 1 but detectable 
(> 20 copies/mL) in batch 2 or 3 
cFailure to suppress – HIV-1 viral load detectable (>20 copies/mL) in batch 1 and batch 2 or 3 
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CHAPTER 6: SYNTHESIS 
This prospective longitudinal study was guided by four key objectives outlined in section 1.9 of the 
introduction, and overall all these were satisfied. Our study has shown that uncontrolled HIV infection 
adversely influences mortality and morbidity outcomes early during the course of CAPD 
management, however, it was not shown to affect catheter patency or failure rates at 18 months. 
Further, HIV-1 particles were shown to be shed in appreciable amounts in CAPD effluents of patients 
with uncontrolled HIV infection as well as in some with suppressed plasma viral loads. 
 
The two primary endpoints of mortality and catheter failure and key morbidity outcomes of first 
peritonitis and hospital admission events were addressed in Chapter 2 (objective 1). Uncontrolled HIV 
infection was shown to increase the mortality risk early during follow-up, with 67% of HIV-positive 
deaths occurring within 120 days of Tenckhoff catheter insertion compared to 38% of HIV-negative 
deaths (p = 0.016). Further, this risk was shown to be influenced by the immunological and virologic 
state of the HIV-positive patient. Those with CD4 counts below 350 and 200 cells/µL were associated 
with higher mortality rates (0.673 and 1.692 deaths/patient-years, respectively) and hazard ratios (HR 
2.67, p = 0.024 and HR 5.39, p < 0.001, respectively) when compared to the HIV-negative cohort. 
However, those with CD4 counts above 350 cells/µL had comparable mortality rates to HIV-negative 
patients (0.274 vs. 0.251 deaths/patient-years, respectively, HR 1.08, p = 0.867). Moreover, those 
with detectable viral loads (1.021 deaths/patient-years, HR 3.63, p = 0.001) and ART commenced 
within 6 months of Tenckhoff insertion (0.714 deaths/patient-years, HR 2.65, p = 0.010) were 
associated with poor mortality outcomes. Detectable HIV viral load and baseline serum albumin and 
ferritin were suggested to be independent predictors of mortality, highlighting the influence 
uncontrolled HIV infection and malnutrition and inflammation factors in predicting mortality 
outcomes.  These observations are in agreement with the few previously published retrospective 
studies [57-59]. However, to our knowledge, our study is the first to show these effects in a larger 
prospective cohort.  
 
Catheter failure outcomes were not shown to be adversely influenced by HIV-infection, as reflected 
by non-significantly differing catheter patency (HIV-positive: 74.6% vs HIV-negative: 77.0%, p = 
0.822) and failure rates (0.298 vs. 0.270 episodes/person-years, respectively, p = 0.822) documented 
in our cohorts at 1 year of follow-up. Further, the types and distribution of complications resulting in 
the removal of Tenckhoff catheters were not significantly different between the HIV-positive and 
HIV-negative cohorts. Infective complications were identified as the predominant cause leading to 
technique failure responsible for 84.6% of HIV-positive cohort catheter failures comparable to 85.7% 
of HIV-negative failures, while mechanical complications accounted for 15.4% and 14.3% of catheter 
failures, respectively. 
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Eighty percent of the HIV-positive cohort had complications during the first year of follow-up 
requiring at least one hospital admission compared to 62.9% of the HIV-negative cohort (p = 0.025). 
HIV-infection was shown to adversely influence all-cause hospital admission rates, as reflected by 
increased incidence rates in the HIV-positive cohort compared to the HIV-negative cohort (2.97 vs. 
1.52 admissions/person-years, HR 1.66, p = 0.013). This morbidity risk was also shown to be 
influenced by the immunological state of the HIV-positive patient with baseline CD4 counts below 
200 cells/µL associated with worse hospital admission outcomes (8.22 admissions/person-years, HR 
3.02, p = 0.001). The HIV-associated morbidity risk was further demonstrated by the higher 
cumulative rate of days spent in hospital in the HIV-positive cohort compared to the HIV-negative 
cohort (25.9 vs. 14.8 days/person-years, IRR 1.47, p < 0.001). Tenckhoff insertion site, diabetes, 
systemic lupus erythematosus, baseline HIV-1 viral load detectability, hemoglobin levels, BMI, serum 
albumin, CRP, serum ferritin, educational level, and employment status were factors independently 
associated with increased cumulative number of days spent in the hospital. These associations 
highlight the importance of malnutrition, inflammation, socioeconomic factors, late presentation, and 
HIV and comorbidities control in determining risk for increased morbidity.  
 
Peritonitis was an important morbidity outcome also shown to be adversely influenced by HIV 
infection. The HIV-positive cohort was associated with a two-fold higher first peritonitis rate 
compared to the HIV-negative cohort (1.668 vs. 0.616 episodes/person-years, HR 2.38; p = 0.001). 
Further, this rate was shown to be 5-fold higher among HIV-positive patients with CD4 counts below 
200 cells/µL compared to the HIV-negative cohort (5.069 episodes/person-years, HR 5.16, p < 0.001), 
highlighting the importance of immunological control in influencing the risk for first peritonitis 
events. This risk was shown to manifest early, with a higher proportion of HIV-seropositive 
participants (41.4% vs. 15.7%, p = 0.001) experiencing peritonitis within 90 days after catheter 
insertion. The primary objective of evaluating the effects of HIV seropositivity on outcomes of CAPD 
among dialysis-requiring renal failure patients was realized, as the effects of HIV infection were 
delineated with respect to mortality and morbidity outcomes. The hypothesis that HIV infection 
increases the risk of catheter failure, morbidity, and mortality among renal failure patients undergoing 
peritoneal dialysis, was shown to be true for morbidity and mortality outcomes but not shown to be 
true for catheter failure outcomes. 
 
Peritonitis outcomes (inclusive of relapse and subsequent episodes) were further explored in chapter 3 
(objective 2). At 18 months, HIV infection was associated with an increased risk of developing 
peritonitis (first and subsequent episodes) with higher overall peritonitis rates reported in the HIV-
positive cohort compared to the HIV-negative cohort (1.86 vs. 0.76 episodes/person-years, HR 2.41, p 
< 0.001). This risk was also shown to be modified by the immunological state of the HIV-positive 
patient, as those with CD4 counts below 200 cells/µL reported a 4-fold increased hazards for 
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peritonitis (3.69 episodes/person-years, HR 4.54, P < 0.001) compared to HIV-negative patients. The 
HIV-associated peritonitis risk was shown to extended to relapse episodes with the HIV-positive 
cohort reporting higher peritonitis relapse rates compared to the HIV-negative cohort (0.298 vs. 0.078 
episodes/person-years, HR 3.88, p = 0.010). Furthermore, the peritonitis risk was shown to persist 
throughout follow-up, as demonstrated by the peritonitis-free survival rate of only 6.0% at 18 months 
compared to 32.3% in the HIV-negative cohort (p < 0.001). On multivariable analysis, HIV infection, 
diabetes comorbidity, and a baseline CD4 count less than 200 cells/µL were found to be independent 
predictors of peritonitis episodes, further, highlighting the importance of HIV-infection and associated 
immunological state and comorbidity in determining the peritonitis risk. 
 
Peritonitis was shown to be the leading cause of catheter failure in both cohorts (82.4% in HIV-
negative and 84.2% in HIV-positive cohorts) and was further identified as an independent predictor of 
this outcome (HR 14.47, p = 0.001). However, HIV infection was not shown to significantly influence 
all-cause catheter failure rates (0.237 and 0.338 episodes/person-years, respectively, HR 1.42, p = 
0.299) and catheter patency (71.4% and 58.2%, respectively, p = 0.295) at 18 months. Associated 
with these observations was a lower proportion of gram-negative peritonitis episodes documented in 
the HIV-positive cohort (27.7% vs. 44.4%, P = 0.038) compared to the HIV-negative cohort. 
Furthermore, gram-negative organisms were identified as the main causative organism group for 
catheter failures in both cohorts (42.1% and 52.9%, respectively). Thus, it was postulated that HIV 
infection might not significantly increase the risk of catheter-threatening peritonitis in the first 18 
months following insertion but instead preferentially increase the risk for treatable peritonitis 
episodes. Further supporting this hypothesis, was the documented increased gram-positive peritonitis 
rate in the HIV-positive cohort compared to the HIV-negative cohort (0.68 vs. 0.26 episodes/person-
years, HR 2.59, P = 0.001), as these types of peritonitis episodes are typically associated with a more 
favourable outcome.  Gram-negative organisms such as Pseudomonas have also been associated with 
very low treatment response rates and cure rates, and very high catheter failure rates compared to 
typical gram-positive organisms in literature reports [48, 49, 71], further supporting the notion that 
gram-negative organisms are the prime catheter-threatening peritonitis organisms.  The second 
objective of evaluating the effects of HIV seropositivity on risk factors, pattern, and incidence of 
peritonitis among peritoneal dialysis patients was realized, as the overall peritonitis rates and 
associated risk factors and the types of organisms likely to cause both infection and technique failure 
were delineated with respect to HIV infection. The hypothesis that HIV infection increases the risk of 
peritonitis complications among renal failure patients undergoing peritoneal dialysis was accepted. 
 
The effects of HIV infection on Staphylococci peritonitis, the predominant gram-positive peritonitis 
type, and on the rates of S. aureus nasal carriage and catheter infections, as important gram-positive 
risk factors, was explored in chapter 4 (objective 3). HIV infection was found to adversely influence 
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S. aureus nasal colonisation, particularly colonisation by MRSA, and CNS peritonitis risk. Although, 
no significant differences in S. aureus nasal colonisation rates were demonstrated in relation to HIV 
(30.5% in HIV-negative cohort and 43.3% in HIV-positive cohort, p = 0.147), the interval between 
Tenckhoff catheter insertion and the first S. aureus nasal detection was significantly shorter in the 
HIV-positive cohort (67.5 days) than in the HIV-negative cohort (251 days) (p = 0.002), highlighting 
an underlying HIV-associated risk for S. aureus nasal colonisation. Furthermore, the MRSA nasal 
carriage rate was significantly higher in the HIV-positive cohort (31.7%) than that in the HIV-
negative cohort (13.6%) (p = 0.018), reflecting, an increased risk for the establishment of MRSA 
colonies in the nares associated with HIV infection. Moreover, CNS nasal carriage was found to be 
significantly lower in the HIV-positive cohort compared to that in the HIV-negative cohort (43.3% vs 
69.5%, p = 0.004), suggesting HIV-associated changes to the usual body commensal patterns 
favouring organisms such as MRSA, which are associated with greater healthcare exposure. 
 
Although, HIV infection was not shown to adversely influence S. aureus peritonitis rates, the HIV-
positive cohort was found to have a higher overall staphylococci peritonitis rate than the HIV-
negative cohort (0.569 vs 0.223 episodes/person-years; HR = 2.58, p = 0.003), due to significantly 
increased CNS peritonitis incidence in the former compared with that in the latter (0.435 vs 0.089 
episodes/person-years; HR = 5.27, p < 0.001). This HIV-associated risk was demonstrated to be 
influenced by the immunological state of the HIV-positive patients, as those with CD4 cell counts < 
200 cells/µL were associated with an even higher rate of staphylococci peritonitis (0.973 
episodes/person-years; HR 4.44, p = 0.009) compared to the HIV-negative cohort. However, good 
treatment response rates were documented in both cohorts, with 93.8% of the HIV-negative and 
96.6% of the HIV-positive staphylococci peritonitis episodes responding to treatment and allowed for 
CAPD to continue. HIV infection was associated with higher all-cause (0.286 vs 0.160 
episodes/person-years, HR 1.72, p = 0.190) and S. aureus (0.156 vs 0.076 episodes/person-years, HR 
1.96, p = 0.240) catheter infection rates compared to HIV-negative state, but, these differences were 
not statistically significant. In the HIV-positive cohort, S. aureus nasal carriers were associated with a 
significantly higher S. aureus catheter infection rate compared with non-carriers (0.302 vs 0.036 
episodes/person-years, HR 8.41, p = 0.047), suggesting that HIV infection enhances the risk of S. 
aureus catheter infections that is associated with S. aureus nasal carriage. The third objective 
evaluating the effects of HIV seropositivity on S. aureus nasal carriage and incidence of staphylococci 
peritonitis and catheter-related infection among renal failure patients undergoing peritoneal dialysis 
was realized, as S. aureus nasal carriage, staphylococci peritonitis and catheter-related infection rates 
were delineated with respect to HIV infection. The hypothesis that HIV increases the risk of 
staphylococci species peritonitis and S. aureus nasal carriage thereby increasing the risk of S. aureus 
peritonitis and catheter infections among renal failure patients undergoing peritoneal dialysis was 
partially confirmed. Although HIV was not shown to increase significantly S. aureus nasal carriage 
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rates, it was associated with a significantly increased MRSA nasal colonisation rate. Furthermore, 
HIV was shown to increase staphylococci species peritonitis but not shown to significantly affect S. 
aureus peritonitis. HIV was not shown to influence significantly catheter-related infections but was 
shown to enhanced the risk for S. aureus catheter-related infections among S. aureus nasal carriers.  
 
The shedding of HIV particles into CAPD effluents in HIV-positive ESRD patients on HAART and 
factors associated with detectability of HIV-1 viral load both in plasma and effluents were evaluated 
in chapter 5 (objective 4). HIV particles were demonstrated to be shed in detectable amounts into the 
CAPD effluents of some HIV-positive patients with unsuppressed and suppressed plasma viral loads. 
A consistent proportion of patients had HIV-1 particles detectable in the CAPD effluents in the 
absence of detectable levels in corresponding plasma samples (3.4% at 45 days, 5.3% at 200 days, and 
10.0% at 377 days, p = 0.417). This finding raises concerns about a localised sanctuary site and 
potential infectivity of some HIV-positive CAPD patients on a full complement of HAART. The odds 
ratio for HIV-1 particle detection in CAPD effluents were significant increased if plasma HIV-1 viral 
load was not suppressed below detectable limits (OR 4.21, p = 0.003). On multivariable logistics 
regression, serum albumin (OR 0.86, P=0.020), BMI (OR 0.81, p = 0.031) and HAART duration >1 
year (OR 0.08, p = 0.013) were identified as protective factors against the detection HIV-1 particles 
on CAPD effluents. Detectable plasma HIV-1 viral load (OR 3.44, p = 0.035), and nevirapine and 
aluvia (Lopinavir/Ritonavir)-containing HAART regimens were shown to be independent predictors 
for the detectability of HIV-1 viral particles in CAPD fluid. Age (OR 0.92, P=0.019), HAART 
duration >1 year (OR 0.22, P=0.045), lamivudine-efavirenz-stavudine containing HAART drug 
regimen (OR 0.05, P=0.024), and having high school or higher education (OR 0.17, p = 0.025) were 
identified as protective factors against detectable plasma viral loads. The fourth objective of 
examining the presence and significance of HIV particles in peritoneal dialysis fluid of HIV-positive 
patients managed with CAPD was realized, as the detectability of HIV particles was established in 
CAPD effluents and the potential risk for infectivity posed by these fluids to immediate family 
contacts was highlighted. The hypothesis that HIV particles are present in the CAPD fluids in 
negligible amount and decrease even further with ARV treatment was not shown to be correct. On the 
contrary, HIV particles were shown to be shed in detectable amounts into CAPD effluents of some 
HIV-positive patients on HAART and even in some patients with a suppressed plasma viral load.  
 
The major limitation of this study was the unavailability of specific causes of death for more than half 
of patients, as deaths occurred outside the study hospital sites and death certificates could not be 
accessed. This absence limited our ability to assess the contribution of catheter-associated 
complications to mortality. However, the discrepancy in dates, which could be less than one month, 
may not have significantly affected our results. Second, regarding the assessment of technique failure, 
the disproportionately higher mortality rate in the HIV-positive cohort contributed to a dropout rate at 
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18 months of 44.3% compared to 21.4% among seronegative patients. This selectively high dropout 
rate may have introduced bias, resulting in a lower apparent rate of technique failure in the HIV-
positive cohort. Furthermore, the short follow-up period may have also contributed to the lack of 
statistical power to appreciate differences in technique failure outcomes. At one year, differences in 
catheter failure rates between the two cohorts were negligible (0.270 vs. 0.298 episodes/person-years, 
HR 1.09, p = 0.822) but at 18 months the two cohorts’ catheter failure rates started to separate (0.237 
vs. 0.338 episodes/person-years, HR 1.42, p = 0.299) but these differences were still not statistically 
significant. Eighteen months may be too short a time to evaluate this outcome adequately. With a 
longer follow-up time and larger sample size, it is conceivable that the differences between the two 
cohorts in relations to catheter failures may become significant. However, the finding of comparable 
catheter patency rates and negligibly differing catheter failure outcomes particularly at one year is an 
important finding which can assist clinicians in evaluating the short-term risks of HIV-infected CAPD 
patients. Lastly, the matching strategy of restricting the inclusion age to 18–60 years may limit the 
generalizability of our results to only this age group. 
 
Conclusion 
This study suggests that HIV infection can adversely influence mortality and morbidity, most notable 
peritonitis, in ESRD patients on CAPD. This HIV-associated risk manifests early in the course of 
CAPD treatment and is modified by the immunological and virologic state of the infected patient. 
Socioeconomic factors, comorbidities, malnutrition, and inflammation, were also suggested to 
influence this risk. HIV infection was not shown to significantly affect catheter failure or patency 
rates at 18 months. However, increased peritonitis rates raise concerns about long-term adverse 
catheter failure outcomes. Furthermore, HIV infection was suggested to increase the risk for MRSA 
colonisation, raising concerns about subsequent drug-resistant infections. Lastly, HIV-1 particles were 
demonstrated to be shed in detectable amounts into the CAPD effluents of HAART-treated ESRD 
patients with unsuppressed, and in some instances suppressed, viral loads, with sociodemographic and 
nutritional factors, and sustained effective HAART regimens suggested to be important in 
determining successful suppression of HIV-1 in plasma and CAPD effluents.  
 
Recommendations and future work 
The current WHO-advocated policy of test-and-treat, also adopted by South Africa in 2016, which 
eliminates the CD4 count threshold for accessing HAART, promises to significantly improve the 
morbidity and mortality of HIV-positive patients including those with renal diseases. This policy will 
hopefully increase the number of patients who are initiated early on HAART before the need for 
dialysis is realized, thereby, improving both the mortality and morbidity outcomes on dialysis. Studies 
on outcomes of HIV-positive patients on haemodialysis also report better survival on HAART in 
particular among those with good HIV infection control [17, 72-74]. However, HIV-infection has 
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been associated with adverse haemodialysis-associated morbidity outcomes [72, 75-77], inclusive of 
haemodialysis catheter-related infections and hospital admissions, analogous to the poor morbidity 
trends observed in the HIV-positive patients on CAPD. Comparison of outcomes of CAPD vs 
haemodialysis in a setting of HIV infection and end-stage renal failure is limited by the fact that there 
is no randomised trial to date addressing the question. Inferences can only be made from 
observational studies of either modality. CAPD can be recommended as an acceptable dialysis 
modality which may be associated with adverse morbidity and mortality outcomes but also 
comparable short-term catheter patency outcomes. Nevertheless, a randomized controlled trial is 
desirable comparing haemodialysis against CAPD associated mortality and morbidity outcomes in 
HIV-positive ESRD patients. Such a study can assist in suggesting the best and cost-effective dialysis 
modality and help guide clinicians starting HIV-positive patients on renal replacement therapy. 
 
The findings on peritonitis outcomes, recommend a role for a prophylactic antibiotic strategy, 
particularly in the first six months following catheter insertion when the peritonitis risk is highest and 
more so among patients with low CD4 counts. However, studies on types of prophylactic antibiotics 
and associated measures that can best help improve peritonitis outcomes are needed and would be of 
great potential benefit in mitigating against the HIV-associated infective risk. Lastly, the findings on 
shedding of HIV-1 particles into CAPD effluents of both virologically suppressed and unsuppressed 
CAPD effluents, suggests extra precautions be recommended to patients with regards to safe disposal 
of their CAPD effluents and associated tubings, as these should be considered infectious even in 
patients on HAART.  Further studies are required to evaluate the pharmacokinetics and effectiveness 
of commonly utilised HAART drugs in CAPD, as well as to investigate the possible causes of failure 
to suppress. 
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APPENDIX 2: INFORMATION DOCUMENT 
INFORMATION DOCUMENT 
Study title:  The effect of HIV infection on the management of renal failure among patients 
undergoing peritoneal dialysis 
Greetings 
I Dr Kwazi C Z Ndlovu am doing research on peritoneal dialysis in renal failure in 
patients with or without HIV.  Dialysis is type of treatment given to patients with non-
functioning kidneys and it performs the cleansing function of the kidney on the body.  
There are two types of dialysis one called haemodialysis where blood is ran through 
a machine which then filters all the unwanted substances from the body. Another type 
is called peritoneal dialysis, where fluid is put into the abdomen (belly) for a specified 
period thereby allowing waste product to be removed from the body by the dialysis 
fluid.  Research is just a tool used to learn the answer to a question. In this study we 
want to learn whether peritoneal dialysis can be used safely and efficaciously to help 
patients with renal failure and also at the same time are infected by the HIV virus. 
 
We are asking / inviting you to participate in this research study (or asking for your permission to 
include your child in a research study). 
 
We are recruiting patients who have severe kidney failure requiring dialysis. We are recruiting both 
patients who are HIV positive as well as those who are HIV negative. All patients in both groups will 
be inserted a peritoneal dialysis catheter. This is a plastic stick inserted into the abdomen (belly). A 
small area below the navel will be cleaned, numbed with a numbing injection and then using a small 
opening the dialysis catheter will be inserted into the belly. Dialysis fluid will be inserted into the belly. 
This process performs the cleansing function of the kidneys in the body. You will then be trained on 
the operation of this dialysis method.  This dialysis method is used routinely in many hospitals both 
here in KwaZulu-Natal as well as throughout the world. This dialysis method has an advantage of 
allowing dialysis to be performed at home by the patient. This is particularly important since there are 
limited slots available in the haemodialysis system.  
 
Like any procedure peritoneal dialysis does have uncommon complications. Very 
rarely internal organs can be damaged during the insertion of the dialysis catheter. 
Sometimes infection in the abdomen can develop later in the course of treatment. 
These complications are not common and every measure possible will be taken to 
minimize risks of such and other unforeseen complications. 
 
If this study produces favourable results we will be able to offer more treatment options to patients 
presenting to King Edward hospital and surrounding hospitals with life threatening renal failure. 
 
Alternative treatments for kidney failure such as haemodialysis are not readily available to all patients 
who need it due to resource constraints. This fact makes it even more important to investigate easily 
implementable and cost effective treatment options. 
Participation in this study does not guarantee acceptance into the chronic renal programme nor will it 
disadvantage any of its participants.  All participants will be worked-up according to local protocols 
and presented to the chronic renal programme committee timeously for consideration. Participation in 
the project will not undermine in anyway the normal care due patients with dialysis requiring renal 
failure. However, participants of the study will be required to answer special questionnaires which have 
been adapted specifically for this project to get more information about the participants that will assist 
in the interpretation of study results at the end of the study. This information will be kept at the strictest 
of confidence and will be secured in a secure room and password protected computer with access 
restricted to the research team. Furthermore, extra blood tests will be drawn from participants 
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amounting to an extra 10ml of blood withdrawn during each visit.  These extra samples of blood will 
test for special biomarkers that are modified by renal failure and inflammation. 
 
Participation is entirely voluntary. You may refuse to participate and that will not invoke any penalty 
or loss of benefits to which you are otherwise entitled. You may discontinue participation at any time 
without penalty loss of benefits to which you will otherwise be entitled. 
 
You are entitled to reimbursements for any “out of pocket” expenses you may have incured as a result 
of participating in this study, e.g. taxi fare. 
 
Confidentiality: Every effort will be made to keep personal information confidential.  Absolute 
confidentiality cannot be guaranteed.  Personal information may be disclosed if required by law. 
Organizations that may inspect and/or copy your research records for quality assurance and data 
analysis include groups such as the Biomedical Research Ethics Committee, Data Safety Monitoring 
Committee and the Medicines Control Council. 
 
For further information / reporting of study related adverse events. 
Contact details of researcher/s – Dr Kwazi C. Z. Ndlovu,  0823388996 
 
Contact details of BREC Administrator or Chair – for reporting of complaints/ problems: 
Biomedical Research Ethics, Research Office, UKZN, Private Bag X54001, Durban 4000 
Telephone: +27 (0) 31 260 4769 / 260 1074 
Fax:   +27 (0) 31 260 4609 
Administrator: Ms D Ramnarain   Email:  BREC@ukzn.ac.za 
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APPENDIX 3: CONSENT DOCUMENT 
Consent to Participate in Research 
 
Greeting: 
 
I Dr Kwazi C Z Ndlovu am doing a comparative research on peritoneal dialysis in renal failure 
patients with and without HIV. 
 
You have been asked to participate in a research study to evaluate the effect of peritoneal dialysis in the 
treatment of severe kidney failure. You will be inserted a peritoneal dialysis catheter. This is a plastic 
stick inserted into the abdomen (belly). A small area below the bellybutton will be cleaned, numbed 
with a local numbing injection and then using a small opening the dialysis catheter will be inserted into 
the abdomen.  Another opening will be made a few centimetres away from the first opening that will 
serve as an exit of dialysis catheter. Dialysis fluid will be introduced into your belly to perform the 
cleansing function of the kidneys. You will be trained on operation of this dialysis method and you will 
be expected to carry it out by yourself at home on discharge from the ward. The effect of this treatment 
and complications will be monitored for the next 18 months. 
 
You have been informed that as a participant in the study you will be given required to answer special 
questionnaires which have been adapted specifically for this project to get more information about your 
background and living conditions. This information will be kept at the strictest of confidence and will 
be secured in a secure room and password protected computer with access restricted to the research 
team. Furthermore, extra blood tests will be drawn from you amounting to an extra 10ml of blood 
withdrawn during each visit.  These extra samples of blood will test for special biomarkers that are 
modified by renal failure and inflammation. 
 
You have been informed about the study by ………………………………………… 
 
You have been informed about any available compensation or medical treatment if injury occurs as a 
result of study-related procedures; 
  
You may contact Dr K Ndlovu at 0823388996 any time if you have questions about the research or if 
you are injured as a result of the research. 
 
You may contact the Biomedical Research Ethics Office on 031-260 4769 or 260 1074 or Email 
BREC@ukzn.ac.za if you have questions about your rights as a research participant. 
 
Your participation in this research is voluntary, and you will not be penalized or lose benefits if you 
refuse to participate or decide to stop at any time. 
 
If you agree to participate, you will be given a signed copy of this document and the participant 
information sheet which is a written summary of the research. 
 
The research study, including the above information, has been described to me orally. I understand what 
my involvement in the study means and I voluntarily agree to participate. I understand that participation 
in this study does not guarantee acceptance into the chronic renal programme nor will it disadvantage 
any me in any way. I have been given an opportunity to ask any questions that I might have about 
participation in the study. 
 
 
____________________      ____________________ 
Signature of Participant                            Date 
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____________________   _____________________ 
Signature of Witness                                Date 
(Where applicable)      
 
 
____________________   _____________________ 
Signature of Translator                            Date 
(Where applicable) 
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APPENDIX 4: DATA CAPTURE SHEETS 
Form 1: Screening data capture sheet 
Screening no Hospital no Base hospital ID number  
     
Name Surname Age 
      
KEH admission date PD ward admission date PD stick insertion date Medical unit Unit Registrar 
     
Race Marital status Gender Employment status 
        
address Home phone 
    
  Cell phone 
    
 
HIV status eGFR PD contraindication Renal programme contraindication 
  Yes / No1 Yes / No1  
Current problems Medical history Drug history 
      
      
      
      
      
Surgical history Social history Smoker Alcohol use 
    Yes / No1 Yes / No1 
    weight height 
        
BP Pulse Temperature urine dipstix urine microscopy PD WCC 
           
 
If HIV 
positive 
Last CD4 count Date CD4  taken On ARV treatment  Yes  / No1 
     
If on ARV 
treatment 
Start date ARV site baseline CD4 count Viral load 
        
 
Study suitability Yes / No1  Study group  
Comments  
 
 
 
 
 
                                                     
1 Please circle appropriate response 
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Form 2: Group 1 enrolment data capture sheet 
Informed Consent taken  By: _______________ Date signed: _____________  
If signed by next of kin    Name: ______________________________________ 
Relationship to patient: ________________________________________________ 
Group 1 
Subject_ID Enrolment no Screening no Date of enrolment 
        
PD stick  insertion date Tenckhoff insertion date PD ward discharge date KEH discharge date     
Name Surname Date of birth 
      
Biometric assessment 
AC MAMC SGA WC height weight BMI 
              
BP Pulse temperature urine dipstix urine microscopy 
         
Initial eGFR Formal GFR 24 hr urine protein 24 hr urine creatinine clearance 
        
Ultrasound kidneys Renal biopsy 
Left   Right     
    
    
 
Current Problem list Current Meds 
    
    
    
Physical examination   
  
  
 
Elisa confirmation CD4 count Viral load ARV naive ARV Start date ARV file number 
     Yes  / No     
ARV treatment site ARV Regimen   
    
 
Renal programme work-up investigations     
WR   ASOT   ESR   CRP   
Complement   ANF   Hepatitis B serology   
Lipid profile    TFT and FT3   
ECG   
Echo/Muga/Mibi scan   
Chest Xray   
Additional 
information  
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Form 3: Group 2 enrolment data capture sheet 
Informed Consent taken  By: _______________ Date signed: _____________  
If signed by next of kin    Name: ______________________________________ 
Relationship to patient: ________________________________________________ 
Group 2 
Subject_ID Enrolment no Screening no Date of enrolment 
        
PD stick  insertion date Tenckhoff insertion date PD ward discharge date KEH discharge date     
Name Surname Date of birth 
      
Biometric assessment 
AC MAMC SGA WC height weight BMI 
              
BP Pulse Temperature urine dipstix urine microscopy 
         
Initial eGFR Formal GFR 24 hr urine protein 24 hr urine creatinine clearance 
        
Ultrasound kidneys Renal biopsy 
Left   Right     
    
    
 
Current Problem list Current Meds 
    
    
    
Physical examination   
  
  
 
 
Renal programme work-up investigations     
WR   ASOT   ESR   CRP   
Complement   ANF   Hepatitis B serology   
Lipid profile    TFT and FT3   
ECG   
Echo/Muga/Mibi scan   
Chest Xray   
Additional 
information  
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Form 4: Subject background questionnaire 
Hospital no: ________________ Subject no: _______________ Group: _______ 
1. Have you ever been diagnosed with renal failure before?   Yes / No 
If yes,  
i) What was the diagnosis? ______________________________________ 
ii) When were you diagnosed? ____________________________________ 
iii) Where were you diagnosed? ___________________________________ 
iv) Was a renal biopsy done? _____________________________________ 
v) Have you received hemodialysis? Yes / No   If so for how long? ________ 
vi) Have you received peritoneal dialysis before? Yes / No    
If yes  
When did you receive it? _____________________ 
For how long did you receive it? _______________ 
Why was it stopped? ________________________ 
2. Have you been diagnosed with Hypertension (High blood pressure) ? Yes / No 
If Yes 
i) When were you diagnosed? _____________________ 
ii) Where were you diagnosed? _____________________ 
3. Have you been diagnosed with diabetes (sugar) ? Yes / No 
If Yes 
i) When were you diagnosed? _____________________ 
ii) Where were you diagnosed? _____________________ 
iii) Are you on insulin? Yes / No  if so for how long? _________ 
4. Have you been diagnosed with any connective tissue disease? Yes / No 
If Yes 
i) What is the specific diagnosis? ______________________ 
ii) When were you diagnosed? ________________________ 
iii) Where were you diagnosed? _______________________ 
5. Do you use pain killers (NSAIDS) such as bruffen, aspirin, or indocid?  Yes / No 
i) How often do you use it? 
Every day  /  2-5 times a week  /  once a week  /  occasionally 
ii) For how long have you been using it? __________________ 
6. Do you smoke? Yes / No 
If yes 
i) When did you start smoking? ________________________ 
ii) How many cigarettes do you smoke per day?____________ 
If no 
7. Have you ever smoked before? Yes / No 
If yes 
i) When did you stop? ________________________________ 
ii) When did you start? ________________________________ 
iii) How many cigarettes did you smoke per day?____________ 
8. Do you drink alcohol?  Yes / No 
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If yes 
i) When did you start drinking? ________________________ 
ii) What kind of alcohol do you drink? ____________________ 
iii) How often do you drink? 
Every day  /  every weekend  /  occasionally 
9. Have you ever used alcohol before? Yes / No 
If yes 
i) When did you stop? ________________________________ 
ii) When did you start? ________________________________ 
iii) How often do you drink? 
Every day  /  every weekend  /  occasionally 
10. What is your occupation? 
Unemployed  /  scholar  /  student  /  employed  /  self-employed 
i) Type of occupation? __________________________________________ 
11. What is your monthly income range? 
0 – R999  /  R1000 – R9999  /  R10,000 – R19,999  /  above R20,000 
12. What was your highest education achieved? 
No schooling  /  primary school  /  high school  /  matric  /  diploma  /  degree 
13. What is your ethnicity? 
African  /  Indian  /  White  /  coloured  /  other: __________________ 
14. What is your home language? 
Zulu  /  Xhosa  /  English  /  Afrikaans  /  other: __________________ 
15. Where were you born?     Township  /  Suburban  /  City  /  Rural area 
Place:___________________ Province___________________________ 
16. Where do you live now?     Township  /  Suburban  /  City  /  Rural area 
Place:___________________ Province___________________________ 
17. What type of housing do you reside in? 
Brick house  /  flat  /  shack  /  rural housing  /  other: _____________________ 
i) How many rooms in house? ______________________________________ 
18. How many people reside with you in the house? ________________________ 
19. What type of floor do you have? 
concrete  /  tiles  /  carpet  /  wooden flooring  /  other: _____________________ 
20. Do you have access to water?  Yes  /  No 
In house tap  /  communal tap  /  river  /  other: __________________________ 
21. Do you have access to sanitation?  Yes  /  No 
In house toilet  /  outside toilet  /  pit lavatory  /  communal toilet  /  other: ______ 
22. What is your marital status?  Single  /  Married  /  Divorced  /  other: __________ 
23. Do you have any children?  Yes  /  No 
If Yes how many: _______ 
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Form 5:Monthly visits questionnaire 
Hospital no: ________________ Subject no: _______________ Group: _______ 
1) Have you been admitted since last visit?  Yes  /  No 
If yes fill in hospital admission record form 
2) Are you constipated currently?  Yes  /  No 
If Yes. For how long? _____________________ 
3) Have you suffered from constipation in the last month?  Yes  /  No 
If Yes. How often?  Daily  /  1-5 times a week  /  1-3 times a month 
4) Have you used stool softener in the last month?  Yes  /  No 
If Yes. How often?  Daily  /  1-5 times a week  /  1-3 times a month 
5) Have you suffered from diarrhoea in the last month?  Yes  /  No 
If Yes. How often?  Daily  /  1-5 times a week  /  1-3 times a month 
6) How is your appetite?  Good  /  Poor 
If Poor For how long: ________________________ 
7) Do you have abdominal pain? Yes / No 
8) Have you had episodes of abdominal pain in the past month?  Yes  /  No 
If Yes. How often?  Daily  /  1-5 times a week  /  1-3 times a month 
9) What is the colour of your PD fluid?  Clear  /  Cloudy  /  Bloody  /  Yellow 
10) Are you still passing urine?  Yes  /  No 
If Yes:  How much urine are you passing per day? _______________ 
11) Do you have any problems with drainage into the PD bags? 
12) How much fluid comes out from the overnight bag? ______________ 
13) How much fluid comes out from the morning bag? ______________ 
14) How much fluid comes out from the midday bag? ______________ 
15) How much fluid comes out from the afternoon bag? ______________ 
16) Have you had episodes of fever in the past month?  Yes  /  No 
17) Have you had episodes of rigors in the past month?  Yes  /  No 
18) Have you had episodes of night sweats in the past month?  Yes  /  No 
19) Have you had episodes of nausea in the past month?  Yes  /  No 
If Yes. How often?  Daily  /  1-5 times a week  /  1-3 times a month 
20) Have you had episodes of vomiting in the past month?  Yes  /  No 
If Yes. How often?  Daily  /  1-5 times a week  /  1-3 times a month 
21) Please list record of food you have eaten in the last 24 hours in next page.. 
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B Breakfast  
L Lunch  
D Dinner  
S Snack  
Time  Place  
H Home  
R Restaurant  
(List Name)  
O Other  
Food  
Be very specific, include 
name brands  
Preparation  
How did you cook it  
What did you add to it 
Serving  
Size  
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Form 6: Monthly visit data capture sheet 
Subject no: __________________ Hospital no: _________________ 
Date: ____________ Visit: _______________ Group: _____________ 
Tenckhoff insertion date: _______________ Membrane type: _______________ 
Kt/v: ______ Residual renal function: __________ GFR: ________________ 
Peritonitis episodes   
Date Microbiology Outcome 
      
      
      
      
      
 
Current PD Prescription    
Time Fluid Duration UF volume 
        
        
        
        
        
 
Total UF volume/24hrs: ________ urine dipstix: ____________________ 
weight: _______ BP: ___________ Pulse: _______ Temp: _______ 
Current Medication 
  
  
  
  
  
 
Complaints: ______________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
Appetite: ___________________ Constipation: _______________________ 
 
Examination 
General: ___________________________________________________________ 
__________________________________________________________________ 
CVS: ______________________________________________________________ 
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Chest: _____________________________________________________________ 
Abdomen: __________________________________________________________ 
Exit site: ____________________________________________________________ 
Tract: ______________________________________________________________ 
Hernia: _____________________________________________________________ 
 
FBC: ______________________ CPM: ___________ ALB: ____ 
Ue: _________________________ LFT:_______________________________ 
PD Prescription   
Time Fluid Duration 
      
      
      
      
      
 
Medication changes 
  
  
  
  
  
 
Comments 
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Form 7: Biochemistry data flow sheet 
Hospital no: ________________ Subject no: _______________ Group: _______ 
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10
th
 M
on
th
 
11
th
 M
on
th
 
12
th
 M
on
th
 
Sodium                             
Potasium                             
Chloride                             
Bicarbonate                             
Urea                             
Creatinine                             
Anion gap                             
eGFR                             
               
HB                             
MCV                             
MCH                             
PLATELETS                             
WBC                             
Neutrophils                             
Lymphocytes                             
               
Albumin                             
Calcium                             
Phosphate                             
Magnesium                             
               
Total Protein                             
Albumin                             
Total Bilirubin                             
ALP                             
GGT                             
ALT                             
AST                             
 
Cholesterol               
LDL               
HDL               
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Hospital no: ________________ Subject no: _______________ Group: _______ 
 
 
13
rd
 M
on
th
 
14
th
 M
on
th
 
15
th
 M
on
th
 
16
th
 M
on
th
 
17
th
 M
on
th
 
18
th
 M
on
th
 
Sodium             
Potasium             
Chloride             
Bicarbonate             
Urea             
Creatinine             
Anion gap             
eGFR             
       
HB             
MCV             
MCH             
PLATELETS             
WBC             
Neutrophils             
Lymphocytes             
       
Albumin             
Calcium             
Phosphate             
Magnesium             
       
Total Protein             
Albumin             
Total Bilirubin             
ALP             
GGT             
ALT             
AST             
Cholesterol       
LDL       
HDL       
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Form 8: Biomarker data flow sheet 
Hospital no: ________________ Subject no: _______________ Group: _______ 
 
 
  
En
ro
lm
en
t 
PD
 w
ar
d 
Di
sc
ha
rg
e 
2 
W
ee
ks
 
1s
t M
on
th
 
2n
d 
M
on
th
 
3r
d 
M
on
th
 
4t
h 
M
on
th
 
5t
h 
M
on
th
 
6t
h 
M
on
th
 
7t
h 
M
on
th
 
8t
h 
M
on
th
 
CRP                       
ESR                       
Ferritin                       
Serum albumin                       
serum NGAL                       
serum IL-1                       
serum IL-6                       
serum TGF-β                       
serum FGF                       
serum hyaluronan                       
serum β-2-microglobulin                       
            
PDE HIV Virology*                       
PDE WBC count                       
PDE Total protein                       
PDE Albumin                       
PDE NGAL                       
PDE IL-1                       
PDE IL-6                       
PDE TGF-β                       
PDE FGF                       
PDE hyaluronan                       
PDE β-2-microglobulin                       
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Hospital no: ________________ Subject no: _______________ Group: _______ 
 
  
9t
h 
M
on
th
 
10
th
 M
on
th
 
11
th
 M
on
th
 
12
th
 M
on
th
 
13
rd
 M
on
th
 
14
th
 M
on
th
 
15
th
 M
on
th
 
16
th
 M
on
th
 
17
th
 M
on
th
 
18
th
 M
on
th
 
CRP                     
ESR                     
Ferritin                     
Serum albumin                     
serum NGAL                     
serum IL-1                     
serum IL-6                     
serum TGF-β                     
serum FGF                     
serum hyaluronan                     
serum β-2-microglobulin                     
           
PDE HIV Virology*                     
PDE WBC count                     
PDE Total protein                     
PDE Albumin                     
PDE NGAL                     
PDE IL-1                     
PDE IL-6                     
PDE TGF-β                     
PDE FGF                     
PDE hyaluronan                     
PDE β-2-microglobulin                     
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Form 9: Renal function and biometric flow sheet 
Hospital no: ________________ Subject no: _______________ Group: _______ 
 
  1
st Visit 6th month 12
th 
month 
18th 
month 
Formal GFR       
 
Residual renal 
function       
 
PTH       
 
 
PET test 2
nd week 3rd month 6th month 9
th 
month 12
th month 15
th 
month 
18th month 
kt/v           
URR           
Membrane 
type       
    
 
Biometric assessment 
     
   1
st Visit 6th month  12th month  18th month  
BMI         
arm circumference 
        
mid-arm muscle 
circumference         
Subjective global 
assessment         
waist circumference         
 
Seropositive Group      
   1
st Visit 3rd month 6th month 9th month 12
th 
month 
15th 
month 
18th 
month 
Date             
CD4             
Viral load             
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Form 10: Hospital admission record. 
Name: ______________________ Surname: ____________________ 
Subject no: _______________ Group: ___________ 
 
Admission 
date 
Discharge 
date Hospital 
CAPD 
related Diagnosis Outcome    
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
 
Comments: _________________________________________________________ 
___________________________________________________________________ 
___________________________________________________________________ 
___________________________________________________________________ 
___________________________________________________________________ 
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